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Abstract
The strategies contract research organizations (CROs) use to develop relationships with
pharmaceutical/biotech company clients are not well defined but can bring drugs to
market faster, safer, cheaper, and with an innovative approach to partnership and
scientific collaboration. Grounded in Porter’s competitive advantage theory, the
comparative advantage theory of competition, and the resource-based view of strategy,
the purpose of this qualitative multiple case study was to explore the lived experiences of
nine key senior level decision makers in the pharmaceutical, biotech, and CRO industries,
selected using a stratified purposeful sampling technique, to determine the benefit of
partnerships between the CRO and client. Data were collected using semistructured
interviews, public company documents, current market research, and literature. The data
were analyzed using Yin’s five-step data analysis process and Moustakas’s modified van
Kaam method. Three themes emerged: defining a strategic/essential partnership,
understanding the benefit of building a relationship, and the study director is an essential
asset. By understanding the importance of business relationships, the intangible value of
human capital, client relationships, and the significance of trust in maintaining
relationships, business leaders can implement strategies that provide business advantage
and competitive value throughout drug discovery/development. By understanding
interactions required for success, partnerships between the CRO and client may lead to
innovations in contracted pharmaceutical research that may not only help save lives but
provide for a healthier and improved quality of life.
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Section 1: Foundation of the Study
Following the economic recession of 2008, mergers and acquisitions, large
pharmaceutical company (pharma) consolidation, and acquisition of
biotechnology/biopharmaceutical companies by pharma created industry dynamics that
resulted in corporate downsizing and economic uncertainty caused by the restructuring of
the pharmaceutical research sector to streamline operations, reduce costs, and improve
efficiencies (Green, 2009). To remain competitive, pharmaceutical research company
leaders focused on the productivity of their research and development (R&D)
investments (PAREXEL, 2013).
Contract research organizations (CROs) were directly and adversely impacted by
client consolidation and tight funding, resulting in overcapacity, pricing pressures, and
project delays, all of which negatively affected revenue (Green, 2009). By improving
process efficiencies and evaluating strategic opportunities and business engagement
between the CROs and pharma, both industries stood to gain as the economy recovered
(Green, 2009). Strategic relationships were part of rethinking of the traditional R&D
paradigm at global pharmaceutical/biotech companies (Miller, 2013). Forward strategic
thinking focused on the CRO assuming more responsibility through strategic
partnerships. As a result, the strategic partnerships between pharmaceutical/biotech
companies and CROs drove flexibility, reduced costs, and expanded expertise
(PAREXEL, 2013). The objective of this research study was to explore the outsourcing
methods used by biopharmaceutical and pharma companies in the preclinical research
industry and understand current and future trends for strategic partnerships.
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Background of the Problem
The financial crisis of 2008 had a substantial negative budgetary impact on
pharmaceutical biotechnology companies. Pharmaceutical and biotechnology companies
found that because of downsizing and restructuring, they no longer had the expertise to
perform scientific/research tasks that they previously accomplished in-house. As a result,
outsourcing increased to supplement or replace the expertise no longer available
internally (Getz, 2014). In 2018, the global biopharmaceutical R&D spending was
projected to reach $172 billion. Approximately $112-117 billion was estimated to be
allocated to the total drug development market opportunity (Bank of America Merrill
Lynch, 2018). William Blair & Company representatives estimated more bullish total
drug development spending of $124 billion in 2018, $130 billion in 2019, and $134
billion in 2020 despite the impact of the COVID-19 pandemic on the industry (William
Blair, 2020). Of the total CRO market size (i.e., 67% of global R&D spend), it was
estimated that 29% of the drug development spend is outsourced to CROs (Bank of
America Merrill Lynch, 2018). Growth in the CRO industry is interrelated to
pharmaceutical and biotechnology company R&D spending.
Similarly, CROs were adversely impacted by the same client consolidation and
tight funding, resulting in overcapacity, pricing pressures, and project delays, all of which
negatively affected revenue (Green, 2009). However, following this period, the demand
for and importance of the CRO grew. Increased outsourcing to CROs resulted in a more
integrated and coordinated engagement between the CRO and pharma (Getz, 2014). This
qualitative study explored the experiences of key decision makers at
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pharmaceutical/biotech companies and CROs to describe and understand the
collaborative approach to science and business that has fostered the strategic partnership
paradigm.
Problem Statement
Following the financial crisis of 2008, increased outsourcing to CROs resulted in
a more integrated and coordinated engagement between the CRO and pharma (Getz,
2014). In 2018, global R&D spending allocated to the total drug development market
opportunity was projected to reach approximately $112-117 billion, of which the CRO
market size (drug development spending that is outsourced and may involve strategic
partnerships) was estimated to be approximately $33 billion (Bank of America Merrill
Lynch, 2018). The general business problem was that the role preclinical CROs assume
in strategic partnerships with their pharmaceutical/biotech company clients is not well
defined. The specific business problem was that some leaders of CRO and
pharmaceutical/biotech companies lack strategies to develop strategic partnerships in the
drug discovery and development process (Harris Williams, 2014).
Purpose Statement
The purpose of this qualitative multiple case study was to explore the strategies
that CRO and pharmaceutical/biotech leaders use to develop strategic partnerships during
the drug discovery and development process. The targeted population consisted of nine
key decision makers at pharmaceutical research companies (large and small pharma),
biopharmaceutical research companies, and CROs in the United States, Europe, and Asia.
The implications for positive social change include the potential to provide an efficient
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and collaborative drug discovery and development process that may result in novel
lifesaving compounds receiving regulatory approval and getting to market faster and
safer.
Nature of the Study
A qualitative study explores possible shared elements and opinions from the
independent inquiry of personal thoughts, attitudes, and perceptions of participants and
provides an in-depth understanding of the social world by asking open-ended questions to
learn about the social circumstances, experiences, perspectives, behavior, knowledge, and
histories of those participants (Kelly, 2016; Ritchie et al., 2014). Researchers use
quantitative research phenomena by testing a theory consisting of construct variables,
which are analyzed by means of mathematically based methods (Barnham, 2015; Yilmaz,
2013). Mixed methods research incorporates quantitative and qualitative elements and is
appropriate for research that includes both types of data (Almalki, 2016; C. B. Gibson,
2017). A qualitative research method was appropriate for this study because it provided
an in-depth understanding of the lived experiences of the participants, derived from firstperson reports (Moustakas, 1994), to determine if strategic partnerships between the CRO
and pharma have been mutually beneficial.
I considered three research designs for a qualitative study examining business
strategies: (a) case study, (b) ethnographic, and (c) phenomenological. A case study
delineates a single individual, group, program, or event and concentrates intrinsically on
it to learn more about a poorly understood situation, phenomenon, or real-world
experience (Freeman et al., 2015; Njie & Asimiran, 2014). Ethnography describes a
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culture’s characteristics through direct observation and interaction with participants
(Mohajan, 2018). Although an ethnographic design would provide an in-depth
description of the pharmaceutical industry’s culture, a more specific understanding of
individual experiences and opinions is needed. Descriptive transcendental
phenomenology allows a researcher to gain meaning from lived experiences,
perspectives, and knowledge (Kelly, 2016; Moustakas, 1994) and to examine business
strategies focused on strategic partnerships, but the sampling methodology and sample
size lead to an ambiguity and randomness that results in less concentrated data that could
make the scope of the research too broad (Njie & Asimiran, 2014). A case study focuses
on the sample (i.e., sample size) that provides the most appropriate, in-depth and upclose, detailed accounts of information by concentrating on the depth and quality of
information obtained rather than the number of research participants (Njie & Asimiran,
2014; Yin, 2014). As such, the multiple case study research design was determined to be
the most appropriate for this qualitative study.
Research Question
What strategies do service providers (i.e., CROs) and pharmaceutical/biotech
companies use to develop strategic partnerships during the drug discovery and
development process?
Interview Questions
Listed below are the interview questions:
1. What do you think the role of a CRO is in a strategic partnership during drug
discovery and development?
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2. What is your strategy in terms of deciding what work (i.e., projects, programs,
etc.) is outsourced to a CRO?
3. How would you describe a strategic partnership with a CRO during the drug
development process?
4. Describe the most important factors that influence your selection of a strategic
partner (ranked from most important to least important).
5. What do you think currently differentiates the preclinical CRO(s) that you
have strategic partnership(s) with and were similar strategies used to develop
that/those relationship(s)?
6. As strategic partnerships evolve, what are your concerns considering your
current partnerships/relationships and the expectations you have now and in
the future?
7. How do you measure the financial success of your outsourcing (strategic
partnership, if applicable) project(s)?
8. How do you assess and manage outsourcing (strategic partnership) risks?
9. Describe the risk-sharing responsibilities/assumptions you currently have with
your outsourcing partner.
10. What else can you add regarding strategies service providers (i.e., Contract
Research Organizations) and pharmaceutical/biotech companies use to
develop strategic partnerships during the drug discovery and development
process?
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Conceptual Framework
The conceptual framework of this case study supported the proposition that the
risk in strategic partnerships formed between CROs and biopharmaceutical and pharma
companies is not shared and that facts demonstrating real benefit are difficult to identify.
The objective of this study was to explore the beliefs held by leaders in such companies
about the phenomenon of strategic partnerships and their effect on project outsourcing.
The concepts and theories that shaped this study include the market-based view (MBV)
of strategy outlined in Porter’s competitive advantage theory (Porter, 1980; Wang, 2014),
the comparative advantage theory of competition (Hunt & Morgan, 1995), and the
resource-based view (RBV) of strategy (Wang, 2014). The amalgamation of these
theories provided the framework for this study.
Porter’s (1980) competitive advantage theory described a strategy where firms
identify activities that could provide the company a competitive advantage. A
competitive advantage strategy can be evaluated in terms of cost leadership,
differentiation, and focus (Porter, 1980). A company’s internal environment is the focus
of the RBV of strategy allowing for competitive advantage and the resources (internal
and external) needed to compete in the market (Wang, 2014). In this study, I explored
how key business leaders within the preclinical pharmaceutical CRO arena apply the
competitive advantage theory when developing strategic partnerships during the drug
discovery and development process.
The comparative advantage theory of competition proposes a set of foundational
premises that explain key macro and micro phenomena better than neoclassical perfect
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competition theory (Hunt & Morgan, 1995). Most salient to this study was the premise
that humans in the role of both consumers of products and managers of companies are
constrained in their self-interest seeking by considerations of what is right, proper,
ethical, moral, and/or appropriate (Hunt & Morgan, 1995). In addition, Hunt and Morgan
(1995) suggested that resources, categorized as financial, physical, legal, human,
organizational, informational, and relational, are the tangible and intangible entities that
enable a company to provide a service that has value for some market segment(s).
Salavou (2015) suggested that strategies of low cost (cost leadership), differentiation, and
focus define how a company develops an advantage with respect to competitors and how
that company can develop relative merits in terms of performance outcomes. This study
ascertained if strategic partnerships result in expected value and risk sharing, or if firms
are inhibited by their self-interests and seek services outside an established strategic
partnership.
Operational Definitions
CDC: The Centers for Disease Control and Prevention (CDC) is a United States
federal agency under the Department of Health and Human Services headquartered in
Atlanta, Georgia. The CDC works to protect public health and safety by providing
information to enhance health decisions, and it promotes health through partnerships with
state health departments and other organizations. The CDC is the United States' national
public health institute and is a founding member of the International Association of
National Public Health Institutes (CDC, 2015).
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CRO: A contract research organization is a service organization that provides high
profile support to the pharmaceutical and biotechnology industries in the form of research
services (e.g., target identification and validation, lead identification and optimization,
preclinical testing and research, clinical research, clinical trials management, and
postmarketing surveillance) outsourced on a contract basis (Bonacci & Tamburis, 2016).
IPO: An initial public offering is the first sale of stock by a private company to
the public. IPOs are often issued by smaller, younger companies seeking the capital to
expand, but can also be done by large privately-owned companies looking to become
publicly traded. Companies often decide to go public to raise equity capital in order to
fund company growth, finance R&D and capital expenditure, pay off existing debt,
and/or gain greater visibility, stronger legitimacy and higher market value (Cirillo et al.,
2018)
NIH: The National Institutes of Health (NIH), a part of the U.S. Department of
Health and Human Services, is the nation’s medical research agency—making important
discoveries that improve health and save lives (NIH, n.d.).
USFDA: The Food and Drug Administration (FDA or USFDA) is an agency of
the U.S. Department of Health and Human Services. The FDA is responsible for
protecting and promoting public health through the regulation and supervision of food
safety, tobacco products, dietary supplements, prescription and over-the-counter
pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions,
medical devices, electromagnetic radiation emitting devices (ERED), veterinary products,
and cosmetics (FDA, 2015).
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VC: Venture capital (VC) is capital (equity financing) provided by investors
(individuals, business angels, corporations, governments, pension funds, and/or venturecapital funds) to small business and start-up firms that have potential high growth
opportunities. Venture capital investments have a potential for considerable loss or profit
but are generally designated for investors who seek to generate a positive return on
investment (Gantenbein et al., 2019).
Assumptions, Limitations, and Delimitations
An assumption is an idea presumed to be true but that cannot be verified by the
researcher (Dahan & Shoham, 2014). Gorylev et al. (2015) defined limitations as
potential weaknesses or general methodological problems of a research study.
Assumptions and limitations are conditions beyond the control of the researcher and
outside of proposed constraints (Bailey, 2014; Bloomberg & Volpe, 2015). Delimitations
relate to the phenomenon; they are both analytical and contextual and are restrictions that
the researcher places to focus the scope of the study (Bloomberg & Volpe, 2015;
Marshall & Rossman, 2016; Rule & John, 2015).
Assumptions
I assumed that the participant pool would be representative of the key decision
makers in pharmaceutical and biotechnology companies. Although these key decision
makers were identified by key market intelligence, the specific decision-making process
within any given company may not be fully understood. It is possible that those identified
as key decision makers were part of a more complicated process by which business
strategy is the result of a collective and not any individual person. Also, I assumed that
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the interview questions in this study would be answered truthfully and that the
participants would be honest, forthright, cooperative, and available for/during the
interview.
Limitations
Data accuracy and completeness was dependent on the level of participation by
the participants and willingness to share company information and strategy. The results
of the study were limited by the honesty and thoroughness of the participants’ responses,
and interview participation was not guaranteed. The participants’ availability to respond
to interview questions in sufficient detail or specific knowledge of the subject may have
limited the results of the study. To maximize participation, most interviews geared
toward business evaluation and trending are accompanied by a monetary honorarium/gift.
Given the target sample size, providing a monetary enticement to maximize participation
was not possible or was not allowed by some of the participants’ employers. As a result,
survey participation may have been less than anticipated, and the sample size may have
consisted of a limited number of participants adequate to establish validity but not able to
offer a larger representation of the population (Bernard, 2013). However, a small sample
size is a common limitation in the validation of any study, regardless of the research
method (Flicke, 2014). The availability of documentation to support the participants’
interview responses may have limited the results of the study.
Delimitations
Delimitations are topics, boundaries, or restrictions that the researcher imposes
prior to the inception of the study to narrow the scope of the research and which cannot
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be controlled by the researcher (Bloomberg & Volpe, 2015; Marshall & Rossman, 2016;
Simon & Goes, 2015). The study delimitations included restricted participant
selection/participation of key senior level decision makers in competitor CROs (i.e.,
CROs in direct competition with my employer that may have had confidentiality
concerns with providing information that could result in an actual or perceived business
advantage/liability). The senior level participants who were interviewed were currently
employed and were assumed to have the experience and breadth of knowledge required
to provide in-depth responses to the interview questions; therefore, no additional
eligibility criteria were required.
Significance of the Study
Contribution to Business Practice
Understanding and improving existing company processes and evaluating
strategic partnerships implemented between the pharmaceutical/biotech companies and
preclinical CROs could result in business opportunities that may be mutually beneficial.
Preferred provider arrangements have enabled global pharmaceutical/biotech companies
to realize cost savings across several fronts including reducing their fixed operating costs,
leveraging operating efficiencies, and enabling collection of research data quickly and
accurately (Miller, 2013).
Strategic partnerships have been portrayed as beneficial to the sponsor companies
implementing them (Parrett, 2013). However, based on the ownership of risk by the client
company, the true benefit associated with the partnership is unknown. By appropriately
understanding the role each company has in the partnership and the risk each company
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assumes, transparency is gained, and clearly defined expectations could improve business
processes and practices.
Implications for Social Change
Strategic collaborations between the pharmaceutical research and contract
research industries have the potential to bring new drugs to market faster, for less cost,
and with improved efficiency because of an innovative approach to business partnership
and collaboration (Green, 2009). Pharma companies and the biotech industry have
increasingly been relying on the CRO to complete FDA required testing as part of the
regulatory submission process (Banerjee & Martin, 2014). Methods for promoting
strategic opportunities and business engagement between the CRO and pharma are
needed in the atmosphere of client consolidation, decreased funding, pricing pressures,
and project delays. To reduce the cost and time of drug development, some pharma
companies have pursued R&D joint ventures and outsourcing (strategic partnership)
strategies (Banerjee & Martin, 2015). Innovation management in CRO-pharma/biotech
collaborations is possible by identifying the existence of different options within an
organization to develop this collaborative innovation. Innovation relates to how an
institution decides to develop this partnership and how efficiently it can produce products
and services that are superior to its competition (Jeng & Pak, 2016). By understanding the
mutual interactions that are required for improved success, strategic partnerships between
pharmaceutical/biotech companies and preclinical CROs may lead to innovations in
contracted pharmaceutical research that may not only help save lives but provide for a
healthier and improved quality of life. These strategic partnerships have the potential to
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help bring pharmaceutical drugs to market faster, cheaper, and with improved efficacy
because of a clear understanding of the role each organization plays in the drug approval
process, the assumed risk each organization assumes in the partnership, and the continued
innovative approach to business partnership and scientific collaboration.
A Review of the Professional and Academic Literature
A literature review is a systematic way of collecting and synthesizing previous
research conducted by scholars and practitioners to map and assess the research area
motivating the aim of the study and justify the research question and problem (Snyder,
2019). The research described in this literature review provided the background
information necessary to explore and understand the strategies used to develop strategic
partnerships in the drug discovery and development process. The literature review begins
with an overview of the drug development process and how outsourcing has and
continues to impact drug development and the role of the preclinical CRO. I discuss
funding and investment trends in the pharmaceutical research industry, and describe how
strategic partnerships with CROs can foster lucrative and opportune financial outcomes.
Porter’s (1980) competitive advantage theory is explained, and the market-based view
strategy and the resource-based view strategy are introduced.
Corporate downsizing and economic uncertainty have caused the pharmaceutical
research sector to restructure and streamline operationally, reduce costs, and improve
efficiency (Green, 2009). Pharmaceutical companies have focused efforts on productivity
from their R&D investments to remain competitive (PAREXEL, 2013). Pharmaceutical
and biotech companies have increased their level of open innovation to improve drug
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development timelines and reduce costs in drug development and commercialization by
improving market capitalization and revenue growth rate (Michelino et al., 2015). The
literature review includes the strategic partnership model and how this could impact
competitive advantage, an analysis of outsourcing effects, risks, and rewards, recent
outsourcing (i.e., CRO) trends during the 2020 global COVID-19 pandemic, and the
future of outsourcing and the preclinical CRO strategic partnership strategy.
Drug Discovery and Development
The pharmaceutical drug discovery and development process is a challenging
undertaking that can take approximately 10 to 15 years and cost $1.0 to $1.5 billion
(Harris Williams, 2014). This process requires sophisticated technology and expertise. To
identify one effective and safe drug, millions of potential compounds and molecules are
screened (Patil, 2016). For every 5,000 to 10,000 potential drugs evaluated, ultimately
only one will receive approval from the FDA (Harris Williams, 2014; see Figure 1).
Given the time and costs associated with drug development, pharmaceutical and biotech
companies have increasingly been outsourcing development and preclinical activities to
remove fixed costs and gain efficiencies (Harris Williams, 2014).
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Figure 1
Drug Discovery and Development Process

Note. The drug discovery and development process is divided into four main phases: prediscovery, discovery (late discovery), preclinical, and clinical trials. A successful IND
application requires that the drug company demonstrate reasonable evidence concerning
safety of the potential candidate molecule. Adapted from “Contract Research
Organization Industry Overview,” by Harris Williams & Company, 2014, p. 1. Copyright
2014 by Harris Williams & Company.

Outsourcing
Outsourcing R&D processes has the potential to lead to cost reduction when
implemented and conducted properly (Yerkic-Husejnovic, 2017). New outsourcing
processes were put in place to ensure seamless workflows to accelerate delivery of new
medicines to patients (Martin et al., 2017). When managed improperly, the outsourcing
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process can add to operational costs, terminated agreements, and strategic loss of internal
R&D growth (Yerkic-Husejnovic, 2017). Outsourcing knowledge-intensive activities to
knowledge process organizations (KPOs) serves to reduce obstacles to the innovation
process (Gupta et al., 2009). Pharmaceutical and biotechnology companies have
generally engaged CROs on a project-by-project basis to manage costs and utilize
internal resources more efficiently (PAREXEL, 2013). Outsourcing to CROs allows
pharmaceutical companies to use only the internal resources that are required at any
given time and subcontract the expertise that they would not usually employ in-house
(PAREXEL, 2013). By strategically outsourcing specific activities, companies can
depend on the expertise of the outsourcing partner, thereby reducing costs associated with
having to introduce innovation. Therefore, these companies strategically benefit from the
KPO/CRO core competencies, economies of scale and scope, and knowledge sharing and
learning (Gupta et al., 2009). Increased efficiency, time-savings, and lower cost have
been the expected outcome of integrated technologies and multifunctional alliances
(Getz, 2014). By focusing on improving the efficiencies of existing processes and
evaluating strategic opportunities, both industries (i.e., pharma and CROs) would expect
to benefit. Both industries form closer ties and business integrations to theoretically build
efficiencies and save money (Henderson, 2013).
Traditional large or midsized companies have usually assumed responsibility for
most of the pharmaceutical value chain from drug discovery/development through
production, marketing, and sales. Hiring contract service providers during the past 20-25
years resulted from the need to access an available and variable head count to adapt to
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peak periods of drug development activity and to gain access to scientific expertise no
longer available internally because of downsizing and other cost saving measures (Getz,
2014). While large and midsized pharmaceutical companies gradually increased
outsourcing efforts, in contrast, emerging pharmaceutical companies, biopharmaceutical
and biotechnology early-stage start-up companies focused on select stages of the
pharmaceutical value chain that required expertise and logistics that they did not have.
This required an earlier, more integrated and coordinated engagement with a KPO/CRO
(Getz, 2014).
As use of outsourcing increased, pharmaceutical and
biopharmaceutical/biotechnology companies implemented more integrated engagements
with CROs to take advantage of expertise in terms of capabilities, technologies,
experience, time/cost efficiency, and regulatory requirements (Getz, 2014).
Representatives of Credit Suisse (2018) reported that 40% of respondents to a market
survey indicated that more than half of their preclinical budget was outsourced to a CRO,
of which nearly 75% of these represent small pharmaceutical or biotechnology
companies. The amount of preclinical budget that is outsourced is an indication that
smaller to midsized biopharmaceutical companies use CROs because they lack the
internal infrastructure that larger pharmaceutical companies already possess. Small and
midsized pharmaceutical and biotechnology companies expected a 4.1% and 6.5%
increase in preclinical budgets in 2018, respectively, compared with a 3.3% increase
expected for large biopharmaceutical companies (Credit Suisse, 2018).
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CRO Industry Overview
Pharmaceutical companies introduced cost saving initiatives to stabilize
profitability levels and maintain operating margins with R&D being a core target (Harris
Williams, 2014). During the economic recession beginning in 2008, CROs were directly
and adversely impacted by client consolidation and tight funding, resulting in
overcapacity, pricing pressures, and project delays, all of which negatively affected
revenue (Green, 2009). Pharmaceutical companies shifted focus to late-stage R&D
development to drive drugs to market and replace lost revenue (Harris Williams, 2014).
This shift in focus to late stage R&D development resulted in decreased total R&D
preclinical development spend of -25%, -8%, -4%, and -2% year-over-year growth from
2009 through 2012, respectively (William Blair, 2018). However, as expected, total
outsourcing to clinical CROs increased, and with increased outsourcing, a more focused
engagement between the CRO and pharmaceutical companies was expected (Green,
2009, William Blair, 2018). CRO outsourcing by pharmaceutical companies across all
therapeutic areas and phases increased 44% between 2007 and 2011 (Henderson, 2013).
The pricing pressure that early stage (preclinical) CROs experienced began to stabilize in
2013 as capacity levels normalized because some large preclinical CROs closed capacity.
Growth in the CRO market is interrelated to pharmaceutical and
biopharmaceutical R&D spending and was expected to be driven by growth in R&D
spending and increased outsourcing of R&D activities (Harris Williams, 2014). In 2017,
William Blair & Company representatives estimated that total R&D spending was $145
billion and would increase year-over-year by 5% to an estimate of approximately $152
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billion in 2018 (William Blair, 2018). Of the total CRO market size (i.e., 67%),
approximately 71% of the drug development spend was still performed in-house, while
the remaining 29% was outsourced to CROs (Bank of America Merrill Lynch, 2018).
R&D budgets were expected to grow an average of 1.8% and 2.1% year-over-year in
2018 and 2019, and 3.0% year-over-year in 2020 (William Blair, 2018). Actual R&D
spending is expected to grow in the low-to mid-single-digit range in 2021 despite the
impact of the COVID-19 pandemic, increasing to above 5.5% in 2022 and 2023 (William
Blair, 2020).
In 2015, the outsourced preclinical market was estimated to be approximately
$3.3 billion with an outsourcing penetration rate of approximately 47% and expected 4year compound annual growth rate (CAGR) of approximately 6% on average for 2016
through 2020 (Harris Williams, 2014; Jefferies, 2015). William Blair & Company
representatives estimated the outsourced preclinical development market to be $4.7
billion for 2018 and $5.1 billion for 2019 representing a 9% and 10% year-over-year
growth rate, respectively, and forecasted the market to be $5.6 billion in 2020 (William
Blair, 2020). The increased growth estimated for 2019 and 2020 are the result of
increased outsourcing of preclinical services as a result of the COVID-19 pandemic.
Year-over-year growth is expected to be 9% for 2020, 8% for 2021, and 7% for years
2022-2025 (William Blair, 2020).
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Table 1
Outsourcing Outlook for 2016 – 2020
Outsourced market

Outsourcing

4-Year CAGR

Jefferies

$3.5B
Size
(2016)
$3.2B

53%
Penetration
42%

(20165%
– 2020)
7%

UBS

$2.9B

44%

3%

William Blair

$3.9B

36%

8%

Average

$3.4B

44%

6%

Credit Suisse

Note. Adapted from “CRO Industry Update,” by William Blair, 2015; and
“Pharmaceutical Svcs. Part II: Growing Pie, Unless Someone Eats a Big Slice,” by
Jefferies, 2014.
The CRO has typically been a service provider delivering single or multiple tasks
on a per-project basis (PAREXEL, 2013). This relationship has evolved to one of
strategic partnership where the CRO provides single or multifunctional support for entire
programs reaching various portions of a pharmaceutical/biotech company portfolio (Getz,
2014). These strategic partnerships (i.e., multiyear, highly integrated engagements
between pharmaceutical/biotech companies and CROs) were created to provide
functional support for entire drug development programs (Brocair Partners, 2013). Large
pharma experienced significant challenges associated with the threat of revenue loss due
to patent expiries, slowing chemistry-based research, and regulatory (i.e., FDA) scrutiny
as the result of serious adverse reactions noted for well-publicized commercialized
compounds. Large pharma has become open to strategies that (a) commercialize
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compounds faster and (b) lower the total cost of developing compounds to
commercialization. These strategies along with the high-throughput capabilities and
expertise possessed by CROs increased the willingness of large pharma to outsource
more of their development work and responsibilities to CROs.
Funding and Investments
Venture capital investors do not expect emerging bio/pharma companies to
commercialize their drug pipeline candidates on their own; rather they anticipate that a
global bio/pharma company will acquire these companies or in-license the
pharmaceutical candidate (Miller, 2017). In 2016, venture capital maintained a pace close
to that seen in 2015 and nearly 60% higher than it was in 2012 (Miller, 2017). Venture
biotech funding was down 6% y/y in the first quarter of 2018 following a 10% increase
year-over-year in 2017 compared to 2016 (William Blair, 2018). Conversely, IPO biotech
industry funding was up 30% y/y in the first quarter of 2018 following a 20% decline in
2017 compared to 2016 (William Blair, 2018). Total biotech industry funding was up
45% year-over-year in the first quarter of 2018 following 37% growth in 2017 (William
Blair, 2018).
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Table 2
Pharmaceutical/CRO Relationships
Contract research organization
Charles River
Pharmaceutical company

Covance

Early stage/preclinical relationship

Abbott

R

Amgen
AstraZeneca

WuXi

S

R

S

R

R

S

Biogen Idec
Bristol Myers Squibb
Daiichi
Eisai
Elan
Eli Lilly

R

GE Healthcare

R
S

Gilead
GlaxoSmithKline

R

R

Johnson & Johnson
Merck

R
R

S

R

Novartis

R
R

Otsuka
Pfizer

R

Roche/Genentech

R

R

Sanofi-Aventis

S

R

Takeda

Note. R = relationships that have been verified through company filings/reports or
information obtained from news articles, industry contacts, etc.; S = ‘Strategic’
partnerships/relationships. Adapted from “Pharmaceutical Svcs. Part II: Growing Pie,
Unless Someone Eats a Big Slice,” by Jefferies, 2014.
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Strategic Partnerships
Business challenges emphasize the need for effective communication and
knowledge dissemination, either between information systems or between people (Pappa
et al., 2009). Open integration has been an objective for the adoption of technology and
collaboration to leverage the benefits of strategic planning. These benefits include
compatible, standardized, and interoperable systems; accessible and transparent data and
information; shared governance, risk, and operating practices; dedicated staffing and
reduced numbers of sponsor staff overseeing execution (Getz, 2014). Specific business
models could foster this strategic engagement allowing for risk-reward sharing
opportunities that afford lucrative and opportune financial partnerships. Some business
relationships result in different levels of involvement. Tactical transactional relationships
do not require the same degree of communication, governance, or detail as more
transformational relationships. Strategic clinical research partnerships were expected to
evolve away from transactional models toward integrated relationships that drive value
through specific alignments and efficiencies (PAREXEL, 2013). Market survey data
collected by Credit Suisse representatives (2018) indicated that the move toward strategic
partnerships continues to be a sustainable trend with preferred strategic partnerships in
place for 82% of respondents.
Festel et al. (2010) analyzed the stimulation of innovation in the pharmaceutical
industry through outsourcing of R&D activities within the drug discovery and
development process. This outsourcing opportunity provides a collaborative partnership
that creates efficiency and improves profitability. Miller (2010) reported that Eli Lilly
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and Company formed strategic outsourcing relationships to help reduce its fixed cost
structure while providing quality development and manufacturing services. Eli Lilly
representatives indicated that the company recognized 20% savings on data management
and monitoring (Parrett, 2013). However, there is evidence that cost savings were not
materializing in these partnerships (Parrett, 2013).
As strategic partnerships evolve, they should provide a strong foundation for
pharmaceutical and biopharmaceutical companies and preclinical CROs to address key
concerns and challenges that are apparent in present CRO-sponsor relationships. Key
factors affecting current relationships are:
•

limited alignment of goal and objectives

•

inadequate number of go-to labs

•

high CRO employee turnover

•

revised study pricing resulting from incorrect cost estimates

•

inadequate and often untimely information sharing

PAREXEL representatives (2013) found that industry executives viewed future
changes in the strategic partnership model would need to be driven by greater
collaboration and improved operational efficiencies. Key factors affecting future
relationships are:
•

dedication

•

risk-sharing

•

value

•

transparency
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PAREXEL representatives (2013) described clinical CROs that chose to engage
in strategic partnerships would need to focus on achieving specific metrics such as
quality and timeliness. Dedication was defined as the CRO’s commitment to the client’s
results and success, and alignment with the company’s specific needs. Risk-sharing
covers a wide range of activities including investment in operational efficiencies such as
technology, processes, staffing, and time as well as financial incentives and penalties
demonstrating that the CRO is vested in shared success. Value was driven by the
expectation that the relationship would yield cost and operational efficiencies without
sacrificing quality. The model also provided for better communication between the two
partners and greater sharing of information and expertise resulting in understood
transparency (PAREXEL, 2013). Credit Suisse representatives (2018) described a
sustainable trend toward strategic partnerships for outsourcing needs.
Strategic forward thinking should focus on the CRO assuming a greater up-front
risk in the drug development process by forming strategic partnerships with pharma. This
risk-sharing model ensures that the CRO is operationally or financially vested in shared
success (PAREXEL, 2013).
Competitive Advantage
Porter’s (1980) competitive advantage theory describes a strategy where firms
identify activities that could provide the company a competitive advantage.
Competitiveness is the tactical strategy for achieving goals and outperforming
competitors (Soloducho-Pelc, 2014). Caiazza et al. (2015) described a firms’
competitiveness as dependent on the creation of knowledge through internal investment
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and adoption/adaptation of external knowledge created by other organizations. Industrial
organization economists propose that competitive advantage is achieved if a company has
a better value creating strategy (i.e., market position) not simultaneously implemented by
concurrent or potential competition, while resource-based view researchers suggest that
competitive advantage is the result of a company’s specific capital and specific
capabilities (Huang et al., 2015; Liu & Huang, 2017; Wang, 2014; Whalen et al., 2016).
These conceptualizations of competitiveness suggest that a service provider is perceived
and evaluated in comparison to other providers (i.e., the competition) in the industry, and
this perception likely contributes to customer loyalty (Baumann et al., 2017). Ultimately,
competitiveness can drive customer loyalty and the level of competition (a market
condition) moderates the relationship between service quality and customer loyalty
(Baumann et al., 2017; Chen, 2015).
Market-Based View
Industry factors and the external market condition are the primary determinants of
an organization’s performance in the MBV of competitive strategy (Porter, 1985; Wang,
2014). Wang (2014) argued that in this model, the sources of value for the organization
are linked to the competitive characteristics of the end-product strategic position and that
position is the organization’s unique attribute that is different from the competition. The
strategic position can be described as how an organization performs similar activities to
other companies, but in very different ways (Wang, 2014). Profitability and performance
are therefore tied directly to the structure and competitive dynamics of that specific
industry (Schendel, 1994; Wang, 2014). In formulating strategy, companies often assess
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competitive advantage based on the external competition using Porter’s (1985) five
forces model (see Figure 2). This model consists of
•

barriers to entry;

•

threat of substitutes;

•

bargaining power of suppliers;

•

bargaining power of buyers; and

•

competitor rivalries (Porter, 1985).
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Figure 2
Summary of Five Forces – Key Drivers

Threat of
new
entrants

Bargaining
power of
suppliers

Rivalry
among
existing
competitors

Bargaining
power of
buyers

Threat of
substitute
products or
services

Note. An industry structure framework is built around five competitive forces that can
impact the sustainability of profits. This framework functions to explain profitability
against bargaining and against direct and indirect competition. Adapted from
“Competitive Strategy: Techniques for Analyzing Industries and Competitors,” by M. E.
Porter, 1980, p. 4. Copyright 1980 by The Free Press.
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Wang (2014) concluded that there is considerable diversity in how strategy is
conceptualized and no clear consensus that any one view is correct. Obtaining a certain
market position involves competitiveness and competitiveness is about the ability to
create competitive advantage using the company’s internal or relational resources
(Baumann et al., 2017; Wang, 2014).
To create a competitive advantage, an organization must understand the benefit
their product provides, the target market and target market needs, and who/what is the
competition. An organization needs to have clear and specific goals, strategies, and
processes to build sustainable competitive advantage. Porter (1985) outlined three ways
organizations achieve a sustainable advantage:
•

cost leadership

•

differentiation

•

focus

Cost leadership is an organizations ability to provide reasonable value at a lower price.
Cost leadership is a competitive strategy aimed at maximizing profits by providing the
best possible product with a low production cost resulting in a higher market share than
the competition (Brett, 2018; Porter, 1985). Differentiation is achieved when an
organization is able to deliver a better product than the competition. Brett (2018)
described this strategy as an organization’s ability to charge higher prices (higher profit
margin) based on a higher quality product, or the customer’s perception of a higher
quality product, compared to the competition. An organization typically achieves
differentiation through innovation, quality, and/or customer service. Focus describes the

31
ability for an organization to understand and service the target market better than the
competition. Focus strategy has two variants: (a) cost focus, and (b) differentiation focus
(see Figure 3). In cost focus, an organization looks for a cost advantage for a specific and
targeted segment of the market, while in differentiation focus an organization looks to
create a differentiated focus for a particular market segment (Brett, 2018). Porter (1985)
suggested that the three strategies are approaches that an organization should consider
when dealing with competition. If an organization attempts to combine an emphasis on
low cost and differentiation and fails to develop one of the three strategies, they will
likely experience below average profits and end up in a weak strategic position (Brett,
2018; Porter, 1985). In some cases, an organization may not have sufficient capital and
market share for the cost leadership approach or may not have the expertise to pursue a
differentiation focus strategy (Brett, 2018). As a result, the organization will not be able
to attract high-end customers and may lose them to other companies who are able to
successfully differentiate (Brett, 2018; Porter, 1985). It is important to identify a
difference between an organization’s usual customer base and an identified segment of
the market otherwise outside of the scope of the organization’s business (Brett, 2018).
Porter (1991) described competitive advantages as two basic types: (a) “lower cost than
rivals” or (b) “the ability to differentiate and command a premium price that exceeds the
extra cost of doing so”.
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Figure 3
Achieving a Competitive Advantage
Source of Competitive Advantage

Cost
Leadership

Differentiation

Cost Focus

Differentiation
Focus

Scope

Broad Scope

Differentiation

Narrow Scope

Cost

Note. Porter’s Competitive Advantage Strategies. Adapted from “Competitive
Advantage: Creating and Sustaining Superior Performance,” by M. E. Porter, 1985, p. 12.
New York, NY: The Free Press.
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Porter (2015) cautioned that organizations that are competing on the same product
have a significant challenge because a truism of competition and strategy is that you
cannot meet the needs of every customer. Competitive strategy is about competing to be
unique. “If you try to meet everybody’s needs, the chances are that you won’t be very
good at meeting anybody’s needs” (Porter, 2015).
Strategic partnerships between a CRO and its client(s) are often the result of
customer loyalty and service quality. Understanding market factors (budgets, timelines,
regulations, etc.) and partnership resources and capabilities allows the formulation of
strategy in response to industry dynamics, potentially resulting in competitive advantage
for both the CRO and the pharmaceutical or biotech client. Lin and Darnall (2015)
suggested that a company’s decision to form a strategic alliance or partnership was
influenced by resource-based and institutional factors. The decision to outsource to a
CRO and often to develop a strategic partnership is many times the result of categorizing
the outsourced project as either an opportunity or a threat. In rationalizing between
options, the outsourcing manager must evaluate their organization’s internal
competencies, capital investments, technology, as well as the competencies, cost, and
technology of the partner being considered (Lin & Darnall, 2015). Evaluation of these
factors will identify the project as being a strategic business opportunity or a business
threat resulting in a business partnership/alliance that is either proactive (opportunity
driven) or reactive (threat driven) (Lin & Darnall, 2015). This process is an example of
the RBV of strategy that focuses on the strategic partnership as a driver for competitive
advantage (Lin & Darnall, 2015; Wang, 2014).
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Comparative Advantage Theory
Hunt and Morgan (1995) introduced the concept of resource advantage as a
counter to the neoclassical theory of perfect competition. Competition involves the
constant struggle for a comparative advantage that will yield a market position of
competitive advantage and superior financial performance (Hunt & Morgan, 1995). This
theory was introduced to explain how a competitive and dynamic market is preferable to
one that is command driven. The comparative advantage theory expands on an
organization’s tangible resources (e.g., land, labor, and capital) to include intangible
competencies such as organizational culture, brand equity, knowledge (e.g., consumer
and competitive intelligence), human capital (e.g., skills and knowledge of individual
employees), and relationships (e.g., with suppliers and customers) that enable the
achievement of superior financial performance (Hunt & Morgan, 1995). A comparative
advantage in resources exists when an organization’s resources enable it to produce a
product that (a)is perceived by the market to have superior value and/or (b) can be
produced at lower costs (Hunt & Morgan, 1995). Figure 4 explains nine possible
competitive positions of an organization relative to a competitor in terms of resourceproduced value and relative resource cost for that value.
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Figure 4
Competitive Position Matrix
Relative Resource-Produced Value

Relative Resource Costs

Lower

Parity

Lower

Parity

Superior

1

2

3

Indeterminate Position

Competitive Advantage

Competitive Advantage

4

5

6

Competitive

Parity Position

Competitive Advantage

7

8

9

Competitive

Competitive

Indeterminate Position

Disadvantage

Disadvantage

Disadvantage

Higher

1
2
3
4
5
6
7
8
9

Demand is heterogeneous across industries, heterogeneous within industries, and
dynamic
Consumer information is imperfect and costly
Human motivation is constrained self-interest seeking
The organization’s objective is superior financial performance
The organization’s information is imperfect and costly
The organization’s resources are financial, physical, legal, human, organizational,
informational, and relational
Resource characteristics are heterogeneous and imperfectly mobile
The role of management is to recognize, understand, create, select, implement, and
modify strategies
Competitive dynamics are disequilibrium-provoking, with innovation endogenous

Note. The marketplace position of competitive advantage identified as Cell 3 results from
the organization, relative to its competition, having a resource assortment that enables it
to produce a product that is (a) perceived to be a superior value and/or (b) produced at
lower costs. Adapted from “The Comparative Advantage Theory of Competition,” by S.
D. Hunt and R. M. Morgan, 1995, Journal of Marketing, 59, p. 7
(https://doi.org/10.2307/1252069).
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Resource-Based View
Porter’s (1985) five forces model enables organizations to structurally analyze
current industry situations. However, this model is limited in assuming a classic perfect
market as well as static market structure (Wang, 2014). In 21st century dynamic markets,
this model is increasingly challenging as industries have become more complex with
inter-relationships that focus on firm-specific determinants of profitability rather than
industry-specific ones (Rumelt, 1991; Wang, 2014). Focus on the capabilities and the
heterogeneous resources that organizations use has become more important than solely
based on products and market positioning as the primary source of competitive advantage
(Rumelt, 1991; Wang, 2014). This approach further describes the RBV strategy.
The RBV of the organization focuses on the internal environment as a driver for
competitive advantage. Kay (2018) described a firm as a collection of capabilities that
provide a more illuminating perspective for understanding the diversity of business
organization over geographies and over time. Porter (1991) argued that the origins of
competitive advantage are valuable, often intangible resources (competencies) that an
organization has such as skills and reputation. An organization’s resources are often
classified as skills, knowledge, and technology (Wang, 2014). A key for achieving
competitive advantage is a business system which harmonizes the resource base, system
of operation, and the range of products offered to achieve effective value-creation (Otola
et al., 2013). Barney (1991) stated that an organizations resources are “all assets,
capabilities, organizational processes, firm attributes, information, etc. controlled by a
firm that enable the firm to conceive of and implement strategies that improve its
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efficiency and effectiveness”. The RBV is a concept that identifies an organization’s
resources and inherent competencies as determinants of its success (Otola et al., 2013).
Barney (1991) indicated that resources that determine competitive advantage should be
valuable, inimitable, rare, and non-substitutable. Otola et al. (2013) further summarized
Barney (1991), Krupski (2011), and Bratnicki (2000) and postulated that that resources
(core competencies) that are strategic should be
•

important and represent a strategic value to the organization;

•

rare in terms of occurrence in current and potential competitors;

•

difficult to be copied by the competitors;

•

have limited mobility;

•

ensure permanent competitive advantage;

•

non-substitutable (irreplaceable); and

•

expensive when imitated.

In the RBV, competitive advantage is created from the efficiency of the resources that
enable the organization to produce greater perceived benefits for the same costs or the
same perceived benefits for a lower cost (Brahma & Chakraborty, 2011).
Porter (1991) provided a counter-narrative and suggests that resources are not
valuable in and of themselves but are valuable because they allow organizations to
perform activities that create advantage in specific markets. The competitive value of
resources can be enhanced or eliminated by competitor behavior, buyer needs, or changes
in technology (Porter, 1991). Peteraf and Barney (2003) explained that the resourcebased view is not a substitute for industry level analytic tools such as five-forces analysis,
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strategic group analysis, or macro environment analysis, but rather a complement to these
tools.
CROs and COVID-19
During the early months of the COVID-19 pandemic beginning in early 2020,
preclinical CROs were largely open for business. However, in some regions of the
country (and world), the restrictions on movement due to COVID-19 caused some
pharmaceutical and biotech companies to slow, and in many cases end, their internal
preclinical activities (BioCentury, 2020). Although representatives of the Department of
Homeland Security included and identified workers conducting research critical to
COVID-19 response as essential critical infrastructure workforce, pharmaceutical and
biotech companies held back from conducting in-house R&D discovery research in favor
of clinical trials or critical investigational new drug-enabling (IND-enabling) studies
(BioCentury, 2020). These companies chose to restrict/limit company access and as a
result, most internal preclinical programs were stopped and ended.
Only 3% of 368 global preclinical CROs indicated they had closed and suspended
operations (BioCentury, 2020). Most (67%) were open and fully operational, and 30%
were open but only minimally staffed and operating at partial capacity (BioCentury,
2020). While 60% of the CRO representatives surveyed by BioCentury indicated they
were working on non-COVID-19 projects, almost 25% had programs related to the
outbreak (BioCentury, 2020).
The COVID-19 pandemic will likely affect the biopharmaceutical industry by
impacting the CRO and biopharmaceutical companies financially, by directly impacting
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production and demand, and by creating market disruption. Continued CRO outsourcing
during the COVID-19 pandemic may provide some pharmaceutical and biotech
companies the opportunity to establish relationships/partnerships with a CRO that may
lead to continued work and outsourcing in the future. As outsourcing continues, a shift in
business priorities may occur that may place more perceived risk on the outsourced
preclinical project not being conducted in-house but may forge a strategic partnership
with the CRO that builds continued trust and a lasting relationship. It is likely that
because of the pandemic, outsourcing will increase in the 2020s and beyond. The
outcome of this outsourcing trend may result in possible structural changes in the drug
development process. As the industry navigates a new post-pandemic normalcy in the
coming years, further research exploring the effects of increased outsourcing and the
partnerships and relationships required to ensure business continuity and financial
success will be possible as data become available.
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Figure 5
Preclinical CROs Open During COVID-19

Fully Operational

Partially Operational

Closed

Note. Most preclinical CROs remain open during the pandemic as pharmaceutical and
biotech companies aim to meet their goals by outsourcing more projects. Adapted from
“CROs Might Be the Engine That Keeps Preclinical Research Moving During COVID19,” by Biocentury Inc., 2020. Copyright 2020 by BioCentury Inc.

Transition
The types of partnerships that CROs are engaging in are changing.
Pharmaceutical companies are now outsourcing entire programs and the CRO is
becoming a permanent supplier of certain critical functions. With the recent budgetary
pressure pharmaceutical and biotech companies are under, there has been a shift to more
strategic outsourcing where CROs are no longer mere service providers, but full-service
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collaborators and strategic business partners. The resulting increased outsourcing has
caused a more focused engagement between the CRO and Pharmaceutical companies,
and this partnership will be a synergistic collaboration that provides incentives for both
industries. However, as a service provider, the preclinical CRO does not share equal risk
in these strategic partnerships. The preclinical CRO has different business interests than
their pharmaceutical/biotech company clients (Parrett, 2013) and as a result, strategic
partnerships must be agreed to and understood with complete transparency. In Section 1,
I provided the background of the problem, the research purpose, the research
methodology, and a review of the scholarly and professional literature.
In Section 2, I include the purpose and method of the study, the application and
implication for business use, and implications for social change. In Section 2, I also
discuss the role of the researcher and study participants, data collection and organization
techniques, as well as describe efforts to ensure the validity and reliability of the research
study. In Section 3, I present the findings of the research and implications for social
change. In Section 3, I also draw overall conclusions and list recommendations for
further study/research.
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Section 2: The Project
Corporate downsizing and consolidation and economic uncertainty led the
pharmaceutical research sector to streamline operationally, reduce costs, and improve
efficiencies (Green, 2009). Pharmaceutical companies are now outsourcing entire
programs and the CRO is becoming a permanent supplier of critical functions (Lin &
Darnall, 2015; Parrett, 2013). With the budgetary pressure pharmaceutical and biotech
companies are under, there has been a shift to more strategic outsourcing where CROs
are no longer mere service providers, but full-service collaborators and strategic business
partners (Getz, 2014; PAREXEL, 2013). By understanding the mutualistic interactions
that are required for improved success, decision makers may be able to improve strategic
collaboration between pharma and CROs, which may lead to scientific innovations in
pharmaceutical research that will not only save lives but provide for a healthier and
improved quality of life. The intent of this qualitative study was to explore and evaluate
current business strategies that have focused engagement between the CRO and pharma
to create synergistic collaborations that are financially and scientifically mutually
beneficial. Based on known data and industry trends, I used a multiple case research
strategy to collect and analyze qualitative data to explore empirical innovative
approaches to strategic collaborations between a CRO and pharma/biotech.
Purpose Statement
The purpose of this qualitative multiple case study was to ascertain the
perceptions and experiences of key industry decision makers regarding the risk associated
with strategic partnerships between the CRO and pharmaceutical/biotech companies. The
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targeted population consisted of nine key decision makers at pharmaceutical research
companies (large and small pharma), biopharmaceutical research companies, and CROs
in the United States, Europe, and Asia. Qualitative data were collected through interviews
of chief executive officers (CEO), corporate presidents/vice-presidents, and/or scientific
directors from the United States, Europe, and Asia. This population was appropriate for
this study because these key industry decision makers provided accurate data describing
the attitudes and experiences they have toward strategic business collaborations with each
other, and how those collaborations have influenced the pharmaceutical research
industry. The implications for positive social change include the potential to provide an
efficient and collaborative drug discovery and development process that may result in
novel lifesaving compounds receiving regulatory approval and getting to market faster
and safer.
Role of the Researcher
Clark and Veale (2018) described that the role of a qualitative researcher is to
collect and analyze data. I collected and analyzed data during this study. In qualitative
research, the researcher’s involvement is defined as participatory and interpretive (Clark
& Veale, 2018). Specifically, as the main source of data collection (i.e., the researcher), I
examined and evaluated current market research and literature and built categories and
themes to organize the information into a coherent and substantive review of the research
topic. As the researcher, I mediated the data collection process by asking questions that
provided insight into the outsourcing aspect of pharmaceutical research. Moreover, I
conducted interviews with participants to evaluate how preclinical CROs view risk
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responsibility as a service provider in strategic partnerships, knowing they have different
business interests than their pharmaceutical/biotech company clients.
In this study, I adhered to the protocols provided in The Belmont Report (National
Commission for the Protection of Human Subjects of Biomedical and Behavioral
Research, 1979) and followed basic ethical principles of (a) respect for persons, (b)
beneficence, and (c) justice. I applied these general principles by (a) providing a consent
form to ensure that the participants understood and were informed of the purpose of the
study, (b) examining whether the research was properly designed and justified on the
basis of a favorable risk/benefit assessment for participating in the study, and (c) creating
a fair selection process for participants. To ensure confidentiality, protect the privacy and
identity of individuals and/or organizations, and to minimize researcher bias,
alphanumeric identifiers were used as pseudonyms instead of participant or company
names, as suggested by Saunders et al. (2015). Further, Sorsa et al. (2015) indicated that
scholarly researchers need to be nonjudgmental, professional, and without any prejudice.
I conducted 30- to 45-minute interviews by phone or through Microsoft Teams as
the data collection method for this study with nine key decision makers in the
pharmaceutical, biotech, and CRO industries. The target population included participants
who were company presidents/vice presidents, CEOs, and directors. Key nonclinical
pharmaceutical industry decision makers were interviewed to gain insight describing the
attitudes and experiences they have toward strategic business collaborations with each
other, what risk responsibilities service providers (i.e., CROs) assume in a
scientific/business strategic partnership, and how those collaborations have influenced the
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pharmaceutical research industry (see Appendix A). The in-depth, one-on-one
semistructured interview technique allowed me to solicit direct answers from the research
participants. The unstructured format of the interview questions allowed participants to
provide thoughtful answers and opinions (Bernard, 2013; Moustakas, 1994).
As a member of the preclinical research field, I interact with key decision makers
at biotech (bio) and pharma companies and can influence their scientific programs and
business strategy. Some of the participants were current or past business clients.
Bracketing mitigates unacknowledged preconceptions related to the research to increase
the objectivity of the project (Taverno Ross & Francis, 2016). The bracketing process
built perspectives for a comprehensive summation of current pharmaceutical research
trends in the context of outsourcing and strategic partnerships. Clark and Veale (2018)
suggested that, during the interview process, the interviewer should avoid leading the
participants’ responses by reacting indifferently to their answers and engaging
conscientiously in a subjective perception of their experience. The interview questions
were open-ended and specifically related to outsourcing and strategic partnerships. The
interviewing process continued until data saturation was reached. Data saturation is
reached when no new information is gained and no new coding or themes are determined
from the interviews (Fusch & Ness, 2015). The interview process begins to replicate
results when data saturation is reached (O’Reilly & Parker, 2013; Saunders et al., 2018).
Evaluation and analysis of the collected information may provide an understanding of the
mutual interactions and risks that are required for improved success between
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pharmaceutical/biotech companies and CROs in efforts to foster business innovations that
will not only help save lives, but also provide for a healthier and improved quality of life.
Participants
The target population included nine participants who were key senior level
decision-makers in the pharmaceutical, biotech, and CRO industries (e.g., company
presidents/vice presidents, CEOs, and directors). I used a stratified purposeful sampling
technique to identify the key decision makers (Bryman, 2016). The participant population
was selected from national and international pharmaceutical research companies, biotech
companies, and CROs throughout the preclinical pharmaceutical research industry. The
selection and solicitation of participants for this study was thoughtful, targeted, and
nonrandom. I contacted participants for interviews directly via Microsoft Teams.
Although a minimum of at least one participant could be studied and deemed an
appropriate sample size in a case study (Njie & Asimiran, 2014), the pursuit of a rich data
sample from each business segment within the preclinical research industry required
purposive sampling from several participants from each business segment to provide the
most in-depth information. Participants were selected from a client database made
available to me by my employer. The participants were selected from appropriate
business segments that represent national and international pharmaceutical research
companies, biotech companies, and CROs, and were initially contacted via email or
telephone using the contact information made available to me by my employer to solicit
participation in this study. The senior level participants who were interviewed were
assumed to have adequate experience and breadth of knowledge, based on position/title
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(e.g., company president/vice president, CEO, and director), necessary to provide indepth responses to the interview questions; therefore, no additional eligibility criteria
were required.
To develop a positive relationship with participants, I notified each participant of
aspects of the research that could influence their decision to participate (Marrone, 2016).
I ensured that each participant was provided complete anonymity by using a pseudonym
(e.g., PharmBio1, PharmBio2, CRO1, CRO2) to conceal the participant’s specific
identity, and ensure that each participant understood and voluntarily agreed to participate
in the research. I provided an informed consent form to each participant after receiving
IRB approval. Drake (2013) indicated that a participant can withdraw from the study at
any time via any form of written communication. Participants were not forced to answer
any questions that they were uncomfortable or unwilling to answer (Rodrigues et al.,
2013).
Research Method and Design
Research Method
A qualitative study design is used to explore possible shared elements and
opinions from the independent inquiry of personal thoughts, attitudes, and perceptions of
participants and provides an in-depth understanding of the social world by asking openended questions to learn about the social circumstances, experiences, perspectives,
behavior, knowledge, and histories of those participants (Kelly, 2016; Ritchie et al.,
2014). Whereas quantitative research is typically objective, tangible, empirical,
deductive, and appropriate to study a topic when knowledge of the subject is already
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known (Antwi & Hamza, 2015), a qualitative research method is used to provide insight
into the motivations, attitudes, perceptions, experiences, and values of participants by
allowing a subjective, open, confidential, and anonymous dialogue from individuals who
may not otherwise share their thoughts and opinions (Kelly, 2016; Smollan, 2015).
Quantitative and qualitative elements constitute mixed methods research and are
appropriate for exploration that includes both types of data (Almalki, 2016; C. B. Gibson,
2017). A qualitative research method was appropriate for this study because it was used
to provide an in-depth understanding of the lived experiences of the participants, derived
from first-person reports (Moustakas, 1994), to determine if strategic partnerships
between the CRO and pharma have been mutually beneficial. Based on known data and
industry trends, empirical innovative approaches to strategic collaborations between a
CRO and pharma/biotech were evaluated. Using deductive reasoning, I evaluated these
business models to determine if risk-reward collaborations can be mutually beneficial. I
evaluated outsourcing trends and general financial information. Additionally, a
qualitative analysis of specific CRO/pharma collaborations provided a general industry
overview of business relationships between pharmaceutical research companies and the
biotech industry and their outsourcing partners (i.e., CROs).
Research Design
I considered three research designs for a qualitative study exploring business
strategies: (a) case study, (b) ethnography, and (c) phenomenology. Case study research
is a strategy of inquiry whereby the researcher investigates a phenomenon to provide an
analysis of the context and processes that define the theoretical issues being studied for a
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group of research participants (Njie & Asimiran, 2014). Case study research is defined by
interest in individual cases rather than the methods of inquiry used, is typically used to
investigate and analyze a single or collective case, and is particularistic, descriptive, and
heuristic (Hyett et al., 2014). A single case study delineates a single individual, group,
program, or event and concentrates intrinsically on it to learn more about a poorly
understood situation, phenomenon, or real-world experience (Freeman et al., 2015; Njie
& Asimiran, 2014). Multicase studies (multiple case studies) include a collection of data
from multiple individual sources such as groups and people (Sugar, 2014). Ethnography
describes a culture’s characteristics (e.g., pharmaceutical industry) through intimate,
often face-to-face, direct observations and interactions with subjects (e.g., interviews and
documentary data), which are triangulated using multiple data sources, and offers a
qualitative approach that results in detailed, inductive, interactive, recursive data
collection and analytic strategies to build comprehensive accounts of different social
phenomenon (Mohajan, 2018). Phenomenology describes experiences as they are lived
from an individual perspective (Moustakas, 1994). The researcher’s aim in case analysis
is to learn strictly from the point of view of the study participant as an immediate state in
consciousness (Creely, 2016; Marshall & Rossman, 2016) that provides the most in-depth
information relevant to the questions that are asked (Njie & Asimiran, 2014).
Although an ethnographic design would have provided an in-depth description of
the pharmaceutical industry’s culture, a more specific understanding of individual
experiences and opinions was needed. Descriptive transcendental phenomenology would
have allowed me to gain meaning from lived experiences, perspectives, and knowledge
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(Kelly, 2016; Moustakas, 1994). Creely (2016) described this Husserlian sense of
meaning as a transcendent attribute of describable consciousness, cogent for a
phenomenological approach to investigative research. However, a phenomenological
design is subjective and integrates the collective views of the researcher and participants
by exploring the emotional and affective reactions experienced by those going through
the phenomenon (Tuohy et al., 2013). This would have been beyond the scope of this
research.
A case study is an embodiment of details about specific subject matter that results
in an intensive analysis of complex social phenomena that allows the researcher to retain
holistic and meaningful characteristics of real-life events (Njie & Asimiran, 2014). The
case study design focuses on a sample that provides the best and the most in-depth
information, where the sample size is less important than the depth and richness covered
by the purposive sampling of a single or a few participants necessary to arrive at
interpretations and conclusions rich in details reflective of the case (Njie & Asimiran,
2014). Further, a multiple case study provides basis for transferability of the same
phenomenon in a variety of contexts that may reveal a broader trend significant on a
wider scale (Rule & John, 2015). A case study research approach was used to draw
conclusions from the experiences of decision makers in the pharmaceutical, biotech, and
CRO industry regarding strategic partnerships/collaborations between CROs and
pharma/biotech companies. I considered the multiple case study research design
appropriate to explore business strategies focused on strategic partnerships.
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Data saturation is reached when new data repeat what was expressed in previous
data (Saunders et al., 2018) and when no new data have been found (Fusch & Ness, 2015;
O’Reilly & Parker, 2013), what Sandelowski (2008) refers to as informational
redundancy. Saunders et al. (2018) suggested a similar description of data saturation as
the point when the researcher begins to hear similar comments repeatedly during
interviews. Strauss and Corbin (1998) assessed saturation as a matter of degree,
suggesting that saturation occurs when further data collection becomes counterproductive
and does not add anything new to the data.
Population and Sampling
The purpose of this qualitative multiple case study was to ascertain the
perceptions and experiences of key industry decision makers regarding the risk associated
with strategic partnerships between the CRO and pharmaceutical/biotech companies. I
used purposive sampling of key decision makers in the pharmaceutical, biotech, and CRO
industries. The data were collected using the purposive sampling technique/method by
conducting interviews with participants selected because of their personal experience or
knowledge of the topic (as recommended by Bryman, 2016, and Cleary et al., 2014) and
examining and evaluating current market research and literature. All of the interviews
were conducted over the phone or via a Microsoft Teams meeting due to the national or
international proximity of the selected key decision maker’s physical location or that of
their company.
Speaking with participants over the phone (or similar communication technology)
provides inherent advantages (compared to face-to-face interviews) which include (a)
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confidentiality, (b) mitigating bias, and (c) promoting flexibility (Morse & Coulehan,
2015). When no new data are obtained from the study participants (saturation) and the
information gathered becomes redundant, the interviewing process is ended as the
required sample size has been met (Cleary et al., 2014; O’Reilly & Parker, 2013). The
required sample size is based on the ability to reach theme saturation without new
concepts or themes emerging (Bryman, 2016; Cleary et al., 2014; O’Reilly & Parker,
2013). The criteria for key decision makers in this study were roles of company
presidents/vice presidents, CEOs, and directors. Participation in the study was voluntary,
and therefore, there was no remuneration for participation.
The population for the study was suitable to evaluate how key industry decision
makers regard the risk associated with strategic partnerships between the CRO and
pharmaceutical/biotech companies. A sample size of nine key decision makers allowed
for comprehensive and substantive data from an appropriate sample distribution of both
national and international pharmaceutical research companies throughout the
pharmaceutical research industry.
In this study, I used the stratified purposeful sampling method. Emmel (2013)
explained that qualitative sampling is an iterative set of decisions throughout the research
process and not a single planning decision. Anney (2014) explained that qualitative
sampling is assumed to be naturalistic and conforms to the inquiry and divergent reality
and purpose of the study in a cohesive logic to develop idiographic knowledge.
Purposeful sampling provides informed perspective that can enhance the quality of
exploration synthesis (Flick, 2015). Information-rich cases (e.g., participants) provide the
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logic and power of purposeful sampling and yield in-depth comprehension rather than
empirical generalizations (Palinkas et al., 2015; Patton, 2015). In stratified purposeful
sampling, maximum variation is critical in providing the widest variety of perspectives
possible within the sampling population and between groups of participants within that
population to allow for comparison (Koerber & McMichael, 2008; Palinkas et al., 2015;
Patton, 2015). I, as the researcher, was reflexive and followed the iterative nature of
qualitative research to make decisions in response to empirical findings and theoretical
developments, as described by Emmel (2013).
Ethical Research
The Walden University Institutional Review Board (IRB) representatives are
responsible for ensuring that all Walden University research complies with the
university’s ethical standards as well as U.S. federal regulations. The IRB reviewed and
approved this study (IRB approval number 10-30-20-0223395) to protect the rights,
interests, and welfare of the study participants, and maintain the ethical standards of the
university (Amdur & Bankert, 2011). The Belmont Report (National Commission for the
Protection of Human Subjects of Biomedical and Behavioral Research, 1979) and its
principles focus on respect for the research participants’ individual autonomy and its
derivative application, informed consent (Tene & Polonetsky, 2016). Informed consent is
further based on the principles of privacy and a process of communication between the
researcher and the research participant that culminates in the authorization or refusal to
participate in a research study (Bhattacharya et al., 2016; Grady, 2015). I notified
participants of aspects of the research that could influence their decision to participate. I
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ensured that each participant understood and voluntarily agreed to participate in the
research. There were no incentives for participation in this study and withdrawal from the
study at any time was an option. An informed consent form was provided to the
participant pool after receiving IRB approval. A participant could have withdrawn from
the study at any time by simply informing me via any form of communication (e.g.,
phone call, email, other form of written correspondence). The consent form included
background information of the study and described the voluntary nature of the study.
The interpersonal capacity to respect each participant should be a primary aim of
the qualitative researcher as it demonstrates esteem for the participants (O’Grady, 2016).
Specifically, protecting the privacy and confidentiality of the study participants was an
important aspect of this research. To ensure confidentiality and protect the identity of
individuals and/or organizations, and to minimize researcher bias, alpha numeric
identifiers (pseudonyms) were used instead of participant or company names (Saunders et
al., 2015). All research data including interviews and any study related documents will be
secured and maintained for 5 years following completion of the study and will then be
destroyed.
Data Collection Instruments
The primary data collection instruments for this study was a qualitative research
interview with each participant and the collection and evaluation of current public
company documents, market research, and/or literature. Since real-world phenomena
cannot be measured by external instruments, Yin (2016) explained that the qualitative
study researcher serves as the principal research instrument to make inferences about
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lived experiences by interviewing the research participants. The in-depth, one-on-one
semistructured interview technique allowed me to solicit answers from the research
participants to approximately 10 questions. The semistructured format of the interview
questions allowed participants to provide thoughtful answers and opinions (Bernard,
2013; Moustakas, 1994). The interview was a social interaction where the validity of the
data was the result of cooperation between the researcher and the study participant and
appropriate congruency with the purpose of the research as explained by CastilloMontoya (2016). I used observation, documentation, and evaluation/interpretation of each
participant’s interview question answers to ensure the reliability, validity, and accuracy in
the study as described by Yilmaz (2013). Each study participant was asked the same
interview questions to ensure consistency. I used an interview protocol (see Appendix A)
that set the overall tone and parameters for the interviews. By implementing an interview
protocol, the reliability of the study was further solidified (Yin, 2014). During and after
the approximate 30-45- minute interviews, I used a reflective journal to make comments
that may further clarify any issues/observations made during the discussions as suggested
by Muswazi and Nhamo (2013).
To ensure that the data collected from participants’ interviews was reliable and
valid, I used member checking to validate that the collected information was accurate.
Member checking is a process where the researcher shares a concise summary of the
collected data with the participant allowing the participant the opportunity to review and
provide clarifications and/or confirmation that the information is accurate (Bekhet &
Zauszniewski, 2012; Harper & Cole, 2012).
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Data Collection Technique
Using a semistructured interview technique, outsourcing trends were evaluated,
business collaborations and partnerships were identified, and supporting information was
collected and analyzed to explore and evaluate current business strategies that have
focused engagement between the CRO and pharma to create collaborations that are
financially and scientifically mutually beneficial. The primary instrument that was used
for data collection was a qualitative research interview method (Marshall & Rossman,
2016) and extensive review of current public company documents, market research,
and/or literature. Using multiple data sources and data collection procedures enhance the
information gathered (Robinson, 2013) and result in further credibility and
trustworthiness through the data triangulation process (Carter et al., 2014; Yin, 2014).
The interviews provided a timely and accurate description of the current attitudes
that key decision makers have toward strategic business collaborations with each other,
and how those collaborations have influenced the pharmaceutical research industry. The
information was collected during Microsoft Teams meeting interviews to obtain opinions,
business strategy and theory, and current views/perceptions. As the principal instrument
in this qualitative multiple case study, I asked specific open ended questions (see
Appendix B) during the interview (Freeman et al., 2015) to (a) elicit information from the
participants, (b) understand the underlying basis for that information, and (c) adequately
appreciate participants’ perceptions (O’Reilly & Parker, 2013). The interviews were
recorded and were then transcribed electronically into text documents using voice
recognition software. Face-to-face interviews (when possible) may have allowed me to
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capture verbal and nonverbal data, behaviors, and/or emotions (Speer & Stokoe, 2014),
but may have also resulted in a smaller sample size (participant pool) and potentially
rushed responses because of the predetermined interview time (duration set by protocol).
To mitigate potential disadvantages of the interview process, participants were
offered the option to participate in a Microsoft Teams meeting interview (video
conference) or simply participate via audio in a Microsoft Teams meeting without the
video capture option. These processes allowed for an environment that can promote
privacy, confidentiality, and the level of comfort/ease most appropriate for each
individual participant. Microsoft Teams meeting interviews were recorded using the
software-recording feature to ensure the accuracy of the participants’ responses. I
continued the interviewing process until data saturation had been reached and no new
data was discovered, as explained and suggested by O’Reilly & Parker (2013), Palinkas
et al., (2015); and Sandelowski (2008).
The member checking process involved reviewing, interpreting, and summarizing
the interview recordings. As suggested by Bekhet and Zauszniewski (2012) and Harper
and Cole (2012), I shared a concise summary of the collected data with each participant
allowing the participant the opportunity to review and provide clarifications and/or
confirmation that the synthesis of their information was accurate and appropriately
represented the content and intent of their responses. Based on follow-up conversations
with each participant, the summary responses were updated as necessary, therefore
confirming the data, and enhancing the dependability and credibility of the research.
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Data Organization Technique
W. Gibson et al. (2014) suggested the use of software to keep track of and
organize data. For this study I created and maintained password-protected electronic data
logs through Microsoft Word and Excel that were used to categorize the data. These
software programs allowed me to code and identify data themes to appropriately
categorize and organize the collected data as suggested by Fusch & Ness (2015) and
Patterson et al. (2014). The electronic data will be stored on a password-protected
universal serial bus (USB) flash drive and computer for 5 years, after which all data will
be deleted and/or destroyed.
I used a reflective journal to document information about the study. The journal
allowed me to go through a reflective process and critical thinking with the ability to selfmonitor, be self-directive and autonomous, while allowing for the development of new
perspectives and potential outcomes as described and suggested by Constantinou and
Kuys (2013) and Peredaryenko and Krauss (2013). The journal also allowed me to use
bracketing to examine preconceived assumptions and/or ideas I may have had about the
phenomenon, as described by Chan et al. (2013).
Data Analysis
Yin (2014) described a five-step process for data analysis when conducting a case
study: (a) compile data, (b) disassemble the data, (c) reassemble the data, (d) interpret the
data, and (e) draw conclusions from the data. Key themes and opinions should emerge
from the data analysis process that should inform the research question. The overarching
research question for this study is: What strategies do service providers (i.e., Contract
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Research Organizations) and pharmaceutical/biotech companies use to develop strategic
partnerships during the drug discovery and development process? Using the open-ended
interview questions should allow responses to be grouped into overarching themes (Irvine
et al., 2013). Descriptive analysis was performed, and any response bias was determined.
Data triangulation is used by researchers to ensure appropriate objectivity by
referencing multiple sources (Denzin, 2012; Patton, 2015; Yin, 2014). Methodological
triangulation was used in this study and involved utilization of data from different
sources including detailed responses from interview questions and data from various
respective company and industry documents. I collected data via interviews, evaluation
of current public company documents, market research, and/or literature. Further, using
Yin’s five step process (described previously) I identified themes, codes, categories, and
descriptions to analyze the data appropriately and efficaciously (Campbell et al., 2013;
Yin, 2014). Through this data analysis, I gained an understanding of specific themes,
patterns, and relationships associated with key words from the participant interviews. I
used these data to evaluate the relationship between the emerging themes and the
conceptual framework as described/suggested by Klag and Langley (2013). I compared
and analyzed responses from the interview process, available company documents,
current market research, and/or literature in order to substantiate the research study, the
collected data, conclusions, and outcomes. By reviewing emerging concepts in the
literature and identifying possible relationships to the identified themes, I analyzed how
they were linked to the conceptual framework and how they related to competitive
advantage.
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The collected data was organized using an electronic filing system based upon the
apha-numeric identifiers assigned to each participant. NVivo (Release 1.4) software was
used to code and identify themes for the transcribed interview data. By using NVivo
software, accuracy and consistency was assured throughout the data analysis process
(Corbin & Strauss, 2015).
Reliability and Validity
Reliability and validity strategies ensure that the research study results are
trustworthy, accurate, replicable, appropriate, and well-founded (Barnham, 2015; Leung,
2015; Tracy, 2013). The quality of the qualitative research is evaluated based on the
credibility (internal validity), transferability (external validity), dependability (reliability),
and conformability (objectivity) of the data (Leung, 2015; Morse, 2015). Reliability and
validity are intended to make qualitative research rigorous; and therefore, trustworthy
(Morse, 2015; Reinecke et al., 2016).
Reliability
Reliability in qualitative research addresses the extent that the results of the study
can be replicated and the consistency of the investigator’s research approach throughout
the investigation (Marshall & Rossman, 2016). Reliability in qualitative studies includes
the dependability, consistency, and repeatability of the data collection, interpretation, and
analysis (Morse, 2015; Zohrabi, 2013). Reliability of the interview process was achieved
through stratified purposive sampling. To be more specific with the term of reliability in
qualitative research, Lincoln and Guba (1985) use dependability in qualitative research,
which closely corresponds to the notion of reliability in quantitative research.
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Dependability of the data collection was ensured by using the modified van Kaam
method for data analysis (Moustakas, 1994). Dependability describes when researchers
replicate previous research by using similar resources in a similar context or background
(Venkatesh et al., 2013). The interview protocol also contributed to the rigor of the study
and further demonstrated dependability. Dependability uses an audit trail concept to
establish the trustworthiness of the research findings (Jones, 2014) and stability of those
findings over time (Anney, 2014). I employed the strategies noted above to ensure the
reliability of the study research.
Validity
In qualitative research, credibility describes the accuracy of the collected data to
reflect the observed social phenomena (Morse, 2015) and the confidence and
believability of that data (Anney, 2014). Data credibility was ensured by the interview
participants using member-checking of their interview responses. Participants were
allowed to review and provide clarifications and/or confirmation that the synthesis of
their information was accurate and appropriately represented the content and intent of
their responses (Bekhet & Zauszniewski, 2012; Harper & Cole, 2012). The memberchecking process confirmed the accuracy and completeness of the interview question
answers (Lub, 2015; Morse, 2015; Wilson et al., 2014), and enhanced credibility and
ensured trustworthiness (Beck, 2014). Confirmation of credibility included
methodological triangulation involving the use of multiple data collection methods as
described by Heale and Forbes (2013) and included (a) a research interview method using
open-ended questions, (b) an extensive evaluation of current public company documents
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and/or market research, and a peer-reviewed literature review, and (c) data analysis and
characterization through coding. Transferability (external validity; generalizability)
describes the applicability of the data to another context or individuals (Leung, 2015;
Morse, 2015; Sousa, 2014). The extent to which others can confirm the study findings to
ensure the data reflect the opinions and experiences of study participants rather than those
of the researcher (as parallel to objectivity) is confirmability (Abdalla et al., 2018).
Hussein (2009) suggested that confirmability and transferability are enhanced by using
methodological triangulation and utilization of data from different sources. The use of
comprehensive, detailed, and consistent processes to collect information (e.g., using
interview questions) and confirm the credibility of the data using peer-reviewed sources,
current market research, and public company information (i.e., triangulation), will
provide the future researcher the ability to repeat/replicate the study results or apply the
study conclusion(s) (Beck, 2014; Heale & Forbes, 2013; Yin, 2014). Confirmability is
linked to dependability and objectivity and is increased by data triangulation (Yin, 2014).
Confirmability ensures that the researcher builds on the audit trail using clear and concise
journal notes to interpret the study data based on the research findings and not personal
biases (Rapport et al., 2015; Zitomer & Goodwin, 2014). Data saturation for this study
was reached when there was enough information to replicate the research (described by
Saunders et al., 2018) and when the point of no new data had been reached (described by
Fusch & Ness, 2015; O’Reilly & Parker, 2013). A main objective of qualitative research
is to provide valid and reliable factors that support the study design and reduce researcher
bias or false interpretations (Bernard, 2013). The study design ensured data validity
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through a controlled, intentional interview process (with informed consent), and by using
logical and observable steps to ensure credibility (e.g., member-checking and
methodological triangulation) and trustworthiness of study results as explained by Tracy
(2013). Bekhet and Zauszniewski (2012) and Denzin (2012) suggest that triangulation be
used to review, compare, and contrast multiple data sources to establish credibility of the
study data and results. I employed the strategies noted above to ensure the validity of the
study research.
Transition and Summary
In Section 2, I provided a detailed review of the research methodology, identified
the study population and participants, and defined the role of the researcher. Ethical
research practices were discussed, and data collection/organization and analysis
techniques were identified. Efforts to ensure the validity and reliability of the research
study were also described. In Section 3, I include a complete report and description of the
study results and evaluation/analysis of the study data. A summary of study findings is
presented and a discussion of the study results, along with study conclusions are
presented. Areas for future research were identified at the conclusion of Section 3.
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Section 3: Application to Professional Practice and Implications for Change
The purpose of this qualitative multiple case study was to explore strategies to
develop partnerships between the CRO and pharmaceutical/biotech companies and risksharing collaborations that aim to provide financial and scientific value and benefits. The
data were obtained from published current market research, and from interviews
conducted with key senior level decision makers in the pharmaceutical, biotech, and CRO
industries selected from national and international companies throughout the preclinical
pharmaceutical research industry. The research findings provide an understanding of the
mutual interactions and risks that are required for improved success between
pharmaceutical/biotech companies and CROs to foster business innovations and strategic
collaborations that will not only help save lives but also provide for a healthier and
improved quality of life.
Presentation of the Findings
The goal of this study was to answer the research question: What strategies do
service providers (i.e., s) and pharmaceutical/biotech companies use to develop strategic
partnerships during the drug discovery and development process? To gain an in-depth
understanding of the business strategies and collaborative processes used in developing
and/or sustaining a partnership, I interviewed nine key senior level decision makers in the
pharmaceutical, biotech, and CRO industries (i.e., company presidents/vice presidents,
CEOs, and directors). These participants were assumed to have adequate experience and
breadth of knowledge, based on position/title, necessary to provide in-depth responses to
the interview questions.
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Yin (2014) described a five-step process for data analysis when conducting a case
study: (a) compile data, (b) disassemble the data, (c) reassemble the data, (d) interpret the
data, and (e) draw conclusions from the data. This data analysis process resulted in key
themes and opinions that informed the research question for this study. By using openended interview questions, I was able to group the responses into overarching themes as
suggested by Irvine et al. (2013).
Denzin (2012), Patton (2015), and Yin (2014) suggested that researchers
reference multiple sources (i.e., data triangulation) to ensure appropriate objectivity.
Methodological triangulation was used in this study and involved utilization of data from
different sources including the detailed responses from the interview questions and data
from current published market research, and/or literature. Through this data analysis, I
gained an understanding of specific themes, patterns, and relationships associated with
key words from the participant interviews. Using semistructured interview questions, I
evaluated outsourcing trends and identified the concepts behind business collaborations
and partnerships to explore and evaluate current business strategies that have focused
engagement between the CRO and pharmaceutical/biotech to create financially and
scientifically mutually beneficial collaborations. I continued the interviewing process
until data saturation had been reached and no new data were discovered.
NVivo software was used to transcribe the recorded interviews. I ensured data
credibility through member-checking, that is, by having the interview participants check
their interview responses (i.e., transcripts). Participants reviewed and provided
clarifications and/or confirmation that the synthesis of their transcribed information
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accurately and appropriately represented the content and intent of their interview
responses. I then used NVivo to code and identify themes from the transcribed interview
data.
I used these data to evaluate the relationship between the emerging themes and
the conceptual framework as described/suggested by Klag and Langley (2013). I
compared and analyzed responses from the interview process, current published market
research, and/or literature in order to substantiate the research study, the collected data,
conclusions, and outcomes as recommended by Anney (2014) and Heale and Forbes
(2013). Descriptive analysis was performed by reviewing emerging concepts in the
literature and using Yin’s five-step process to analyze how they were linked to the
conceptual framework and how they related to competitive advantage and a strategic
partnership.
Once the data were coded and patterns and relationships associated with key
words from the participant interviews were identified, key categories emerged identifying
relationships and themes. Analyzing the data further, I established three overarching
themes: (a) defining a strategic/essential partnership, (b) understanding the benefit of
building a relationship, and (c) the study director is an essential asset. These themes were
used to answer the research question.
Analysis of the coded data resulted in specific words and key phrases that
suggested a relationship between emerging concepts and ideas, and how they potentially
were linked to the conceptual framework of the study and strategic partnerships. The
incidence of key words/phrases that described factors that affect or influence an existing
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or potential strategic partnership were tabulated and used to identify key thematic
responses from each individual participants’ interview and collectively across all
participant interviews (see below).
Table 3
Overarching Themes – Participant Interviews
Theme 1
Defining a
strategic/essential
partnership
6

Theme 2

Theme 3

Understanding the benefit of
building a relationship
4

The study director is an
essential asset
0

CRO2

1

6

4

CRO3

5

3

1

CRO4

9

1

3

CRO5

8

2

0

PharmBio1

1

4

2

PharmBio2

1

0

6

PharmBio3

3

5

2

5

1

11

39

26

29

4.3

2.9

3.2

41.5

27.7

30.8

Participant
CRO1

PharmBio4
Total Responses

a

Meanb
Total (%)
a

c

Incidence specific thematic response was recorded (sum of all individual participant

interviews).
b

Average of the incidence for specific theme response across all participants.

c

Percentage of specific theme total response across all themes (i.e., sum of total

responses, all themes).

Analysis of the participant interviews and the resulting key categories of specific
words and phrases identified three overarching themes. For Theme 1, there were 39

68
responses by the nine participants that included the term partnership(s). This represents
an average of 4.3 responses per study participant and a total of 41.5% of all responses by
all study participants across all key themes. For Theme 2, there were 26 responses by
eight participants that included the term relationship(s). This represents an average of 2.9
responses per study participant (nine total study participants) and a total of 27.7% of all
responses by all study participants across all key themes. For Theme 3, there were 29
responses by seven participants that included the terms study director(s). This represents
an average of 3.2 responses per study participant (nine total study participants) and a total
of 30.8% of all responses by all study participants across all key themes.
Theme 1: Defining a Strategic/Essential Partnership
The move toward strategic partnerships continued to be a sustainable trend with
preferred strategic partnerships in place for 82% of respondents in market survey data
collected by Credit Suisse representatives (2018). These innovative outsourcing
opportunities provide for collaborative partnerships that create potential efficiencies for
R&D activities within the drug discovery and development process and improved
profitability for the outsourced partner (i.e., CRO).
The word partnership(s) was used a total of 39 times across all nine study
participants, which represents an average response of 4.3 times per participant for this
specific theme and 41.5% of total responses across the three overarching themes (see
Table 4). The key word partnership(s) was used 269 times across all nine study
participants and was most used by participant CRO3 (mentioned 46 times).
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Table 4
Incidence of Individual Participant Response to Theme 1 and Key Words
Theme 1

Key words

CRO1

Defining a
strategic/essential
partnership
6

CRO2

1

1

3

3

0

CRO3

5

26

10

2

4

CRO4

9

12

4

10

0

CRO5

8

16

0

12

4

PharmBio1

1

5

3

5

2

PharmBio2

1

2

7

2

2

PharmBio3

3

5

4

5

8

PharmBio4

5

15

5

5

0

Total
responsesa
Meanb

39

90

37

46

21

4.3

10

4.1

5.1

2.3

41.5

NA

NA

NA

NA

Participant

Total (%)

c

Partnership

Partner

Strategic

Transaction(al)d

8

1

2

1

Note. NA = Not applicable.
a

Incidence specific thematic response/key phrase was recorded (sum from all individual

participant interviews).
b

Average of the incidence for specific theme/key phrase response across all participants.

c

Percentage of specific theme total response across all themes (i.e., sum of total

responses, all themes).
d

Business model/concept between the CRO and a pharmaceutical company/biotech

company.
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In defining what a partnership is between a pharmaceutical company/biotech
company and a CRO, and the role that the CRO has in that partnership during the drug
discovery and/or development process, study participants were generally in agreement
with a few slight distinctions. Study Participant CRO5 described a strategic partnership
as “providing some sort of value above and beyond the transactional relationship that
occurs in the industry in general.” Additionally, participant CRO5 stated the following:
From our perspective, a strategic partnership, and we don't typically use this
terminology, preferred partners, strategic partnership, really what it is, is that it's
just a relationship, just developed [sic] a relationship to the point to where when
you end up with a hurdle, be it price, regulatory, timing, et cetera, that you can
work together with that individual to focus on the solution and not the problem.
It's really purely a relationship.
Study Participant PharmBio3 explained a strategic partnership by stating the following:
I think large companies are looking for any way that they can leverage that,
whether it's continuing to be transactional or whether it's trying to build more
strategic partnerships, outsourcing operations, it's generally financially good for a
pharma company. Most of the time, CROs can do things cheaper, quicker, better
than pharma companies can internally, because that's what CROs do. It's in their
wheelhouse. I mean, that's the core competency, whereas pharma companies do a
lot of other stuff.
Study Participant PharmBio4 described a strategic partnership in terms of capacity
constraints and indicated, “And so that's a piece of the equation for the strategic
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partnership, is to take advantage of the facilities that are built [i.e., existing CROs] to take
on big studies with lots of animals.”
The phrase strategic partnership was used a total of 19 times by seven of the nine
study participants. Fourteen of the 19 references (73.7%) were made by three participants
representing the CRO industry and the remaining five references (26.3%) were made by
the four participants representing the pharmaceutical/biotech industry. This suggests that
the CRO participants overwhelmingly consider the concept of partnerships to be
strategic. The word transaction or transactional was used a total of 21 times by six of the
nine study participants to describe a business process/collaboration between the CRO and
a pharmaceutical company/biotech company. Nine of the 21 references (42.9%) were
made by three participants representing the CRO industry and the remaining 12
references (57.1%) were made by three participants representing the
pharmaceutical/biotech industry. Only one CRO participant and one
pharmaceutical/biotech participant (two of nine total participants) described a partnership
as generally transactional in nature. Similarly, one CRO participant and one
pharmaceutical/biotech participant (two of nine total participants) considered a
partnership as not transactional. The remaining two participants, one CRO participant and
one pharmaceutical/biotech participant, described a partnership as likely transactional
early in process, but evolving beyond transactional with time. Study Participant CRO3
explained the following:
Ideally, in a partnership, we should evolve. We should evolve into a relationship
that goes beyond simply just transactional. However, I do think that a lot of
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innovators still treat that partnership as a simple transaction, and I don't know that
that partnership is still depending on the client. I think different sponsors are more
or less comfortable in their control and oversight over that product or project. I
think there are different levels of, basically, trust that exists in that paradigm. But
in what I would say is certainly a more elegant, a more sophisticated measure of
partnership, one that if you kind of, and we've all seen scenarios that are most
slow, show slopes of that evolution of a partnering relationship [sic]. I think a true
partnership is where you are part of each other's team. A CRO would simply be
an extension of that sponsor’s team. They would be treated with respect. They
would be treated with accountability. They would be expected to not only do a
job, but to help innovate, to help create value. Not simply a pair of hands, but
really helping to contribute intellectual property that helps not only the CRO be
successful, but certainly helps the sponsor to be successful.
Study Participant PharmBio1 further explained, “The sponsor [i.e.,
pharmaceutical/biotech client] doesn't just treat it as buying a product, right? It's actually,
it's not transactional, it's a relationship. So that to me is the overall theme of all this stuff.
And that's what I look for.”
The general sentiment that a partnership, or perceived partnership, is an evolution
from a typical transactional process to an established relationship with the client, supports
a similar evolution from a market-based view of competitive strategy to a resource-based
view of comparative advantage. Comparative advantage expands on an organization’s
tangible resources to include intangible competencies such as organizational culture,
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brand equity, knowledge (e.g., consumer and competitive intelligence), human capital
(e.g., skills and knowledge of individual employees), and relationships (e.g., with
suppliers and customers) that enable the achievement of superior financial performance
(Hunt & Morgan, 1995). The evolution of a partnership into the intangible competency of
a client relationship may likely define future business strategy for the industry. It is this
resource (i.e., the partnering client relationship) that has the potential of becoming a
comparative advantage for an organization resulting in a resource-produced superior
value relative to what the competition can offer. Rahman et al. (2019) described an
intangible resource as one that allows an organization to attain and sustain competitive
advantage. The evolved client relationship becomes a valuable and inimitable resource
that is used to gain an edge over competition.
Theme 2: Understanding the Benefit of Building a Relationship
The suggested evolution of a partnership to a more focused relationship is a trend
that has occurred or is occurring in the industry. Miller (2013) explained that strategic
relationships were part of rethinking of the traditional R&D paradigm at global
pharmaceutical/biotech companies and this forward strategic thinking focused on the
CRO assuming more responsibility. Typically, the CRO has been a service provider
delivering single or multiple tasks on a per-project basis (PAREXEL, 2013). Getz (2014)
described that this relationship has evolved to one of a strategic partnership where the
CRO provides single or multifunctional support for entire programs reaching various
portions of a pharmaceutical/biotech company portfolio.
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The word relationship(s) was used a total of 26 times in the context of an
overarching theme across eight study participants, which represents an average response
of 2.9 times per total participants for this specific theme and 27.7% of total responses
across the 3 overarching themes (see Table 5). The specific key word relationship(s) was
used 94 times across all nine study participants and was most used by participants CRO3
and PharmBio1 (mentioned 15 times each). Fifty-seven of the 94 references (60.6%)
were made by the five participants representing the CRO industry and the remaining 37
references (39.4%) were made by the four participants representing the
pharmaceutical/biotech industry.
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Table 5
Incidence of Individual Participant Response to Theme 2 and Key Words
Theme 2

Key words

Participant

Understanding the
benefit of building a
relationship

Relationship(s)

Risk

Trust

CRO1

4

11

7

1

CRO2

6

14

6

1

CRO3

3

15

20

4

CRO4

1

4

9

6

CRO5

2

13

5

0

PharmBio1

4

15

16

6

PharmBio2

0

6

7

7

PharmBio3

5

13

3

0

1

3

7

4

26

94

80

29

Meanb

2.9

10.4

8.9

3.2

Total (%)c

27.7

NA

NA

NA

PharmBio4
Total responses

a

Note. NA = Not applicable.
a

Incidence specific thematic response/key phrase was recorded (sum from all individual

participant interviews).
b

Average of the incidence for specific theme/key phrase response across all participants.

c

Percentage of specific theme total response across all themes (i.e., sum of total

responses, all themes).
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In describing a relationship between a pharmaceutical company/biotech company
and a CRO, and the role that the CRO has in that relationship during the drug discovery
and/or development process, most study participants used the terms partnership and
relationship interchangeably. Upon further inquiry, specific participant responses were
noted that support the evolution to the relationship paradigm. Study Participant CRO2
indicated the following:
I've really never been part of what I would say was a true partnership. Every CRO
uses that word and even clients will sometimes use words like “we're looking for
a partner.” You're looking for a provider that you will have a good relationship
with. I think this is somewhat different than being a partner.
Participant CRO2 also stated, “I think the term [partnership] is overplayed by both
industry and pharma and CRO. It's a close, very close working relationship…” Study
Participant CRO3 previously described the evolution of the partnership to a relationship
and added the following:
Ultimately, that relationship is founded in the shared vision and mission of really
having a benefit on all of our mutual customer [sic], which is the patient who
desperately, desperately deserves for a world class partnership. Because I think
that the better we can truly partner, we will deliver a higher quality product to the
patient and we will deliver it faster. And that will take time off of an already long
drug development cycle, which saves lives.
Many of the participant responses that described a relationship alluded to trust or
establishing trust. The word trust was used 29 times by seven of the nine study
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participants. Twelve of the 29 references (41.4%) were made by four participants
representing the CRO industry and the remaining 17 references (58.6%) were made by
three participants representing the pharmaceutical/biotech industry. Study Participant
CRO4 indicated the following:
I think that is first and foremost, most important when people are talking about
being strategic partners. Because I do think to the point of partnerships, we're
talking about it being a give and take, and you have to trust that your partner is
giving and taking as much as you are and doing absolutely what's best in the name
of accuracy and speed to drug development.
When asked what differentiates the preclinical CROs that they are doing business with
(i.e., strategic partnerships/relationships), participant PharmBio1 stated the following:
I think the differences lie in the trust and the personal relationships that are built.
Honestly. I think most CROs are highly capable of doing the work. They all can
do it. Many have been around for a long time and some have, of course, acquired
others that have been around a long time. And so the subject matter experts, the
experienced study directors and study teams are there at all times. So they can all
do that. It's the communication, the support that you get.
Study Participant PharmBio1 further summarized/reflected on the interview by saying the
following:
I think the overall theme for me is to have and build a relationship with the study
team and the SME [subject matter expert] at a CRO. Providing that comfort and
trust that I know the study is getting executed. I like to say things are going to
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happen…Something's going to happen [sic]. But you trust that the study team is
experienced. They know how to respond to it. They communicate all those sorts
of things.
When asked to describe a strategic partnership with a CRO, Study Participant CRO3
explained the relationship as follows:
The heart of the question is that, partnership means, if you asked one hundred
different sponsors or even one hundred different innovators, that might mean
something different to each of them, because it's a personal question. So in my
mind, a partnership should be more than just a transactional relationship. And the
optics of, “oh, you're important to us” and it's kind of fake and somewhat
superficial [sic]. So in my ideology, my theology, a partnership is at the most
simple level, it's where I think there is a higher level of intimacy. There's a higher
level of trust, a higher level of just vulnerability where we're more willing to
share, to act, all the action words that my brain is thinking of. And also the
sponsor is as well. I mean, we're just more forthcoming. We're more vulnerable.
This concept of a built upon and evolved relationship with a seeded establishment
of trust between the CRO and the pharmaceutical/biotech client further supports a
resource-based view of the organization that focuses on the internal environment as a
driver for competitive advantage. Porter (1991) argued that the origins of competitive
advantage are valuable, often intangible resources (i.e., competencies) that an
organization has such as skills and reputation. As previously defined, the comparative
advantage theory expands on an organization’s tangible resources to include intangible
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competencies such as organizational culture, brand equity, knowledge (e.g., consumer
and competitive intelligence), human capital (e.g., skills and knowledge of individual
employees), and relationships (e.g., with suppliers and customers) that enable the
achievement of superior financial performance (Hunt & Morgan, 1995). By
understanding the benefit of building a client relationship, an organization can focus on
the intangible resources necessary to create a lasting competitive advantage. Rahman et
al. (2019) described this type of resource as valuable and nonsubstitutable.
An established relationship built on trust still presented a level of risk associated
with aspects of a project outside the direct control of the pharmaceutical/biotech company
(e.g., regulatory requirements). The relationship also allowed for a level of internal risk
mitigation for these regulatory concerns through the outsourcing process. The word risk
was used a total of 80 times by all nine study participants. Forty-seven of the 80
references (58.8%) were made by the five participants representing the CRO industry and
the remaining 33 references (41.2%) were made by the four participants representing the
pharmaceutical/biotech industry. Study Participant PharmBio2 stated the following:
From my perspective as a sponsor [i.e., pharmaceutical/biotech company] and
having worked at a CRO, I think that the sponsor in the current environment has
one hundred percent of the risk in that relationship [partnership] and because of
that, the individual study director and the relationships that I have with that person
are paramount and my trust of that person and the level of expertise.
Describing risk and risk mitigation, Study Participant CRO3 indicated the following:
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Pharmaceutical companies have elected to outsource some aspects of their work
to partners, contract research organizations…the reasons for that desire to
outsource could vary based on capacity. It could vary based on speed, on value. It
could even be a motivation based on minimizing the pharmaceutical companies’
internal risk and kind of putting that a little bet on the shoulders of a partner.
Study Participant CRO3 further explained:
Small mid-tier biotechs, most of these facilities, many don't even have a lab. So
partnering with a contract organization isn't an option. It's a requirement. But even
organizations that do [have an on-site lab], they may elect to outsource work
based on, again, on the capacity of their resources internally, their expertise
within that area. And many cases, though, I think what has driven a lot of
outsourcing is the fact that, frankly, suppliers can often do that, work more cost
effectively and in many instances more expeditiously than many of the sponsors
can do themselves…But then I also commented on risk. And some of this is just
regulatory risk, you know, particularly in a highly regulated, non-clinical
environment, I think outsourcing work to a supplier like, you know, a large
contract research organization or any size organization is also a way of potentially
mitigating some internal business risk.
This intangible competency, that being the relationship with the skills and knowledge of
the study director (i.e., human capital), may be key for achieving competitive advantage
and effective value-creation.
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Theme 3: The Study Director is an Essential Asset
Strategic partnerships between a CRO and its client(s) are often the result of
customer loyalty and service quality. Lin and Darnall (2015) suggested that a company’s
decision to form a strategic alliance or partnership was influenced by resource-based and
institutional factors. Focus on the capabilities and the heterogeneous resources that
organizations use has become more important than solely based on products and market
positioning as the primary source of competitive advantage (Rumelt, 1991; Wang, 2014).
The RBV is a concept that identifies an organization’s resources and inherent
competencies as determinants of its success (Otola et al., 2013). Barney (1991) indicated
that resources that determine competitive advantage should be valuable, inimitable, rare,
and non-substitutable. Rahman et al. (2019) explained that these resources can be divided
into two performance categories: resources that allow organizations to attain competitive
advantage and others which enable organizations to sustain competitive advantage. In
evaluating the data collected from the participant interviews conducted for this study, an
interesting and unexpected theme emerged from the participant responses; that of the role
and significance of the study director. The study director resource can function to attain
competitive advantage by providing valuable and rare attributes for an organization. The
study director can also provide inimitable and nonsubstitutable attributes that help an
organization sustain competitive advantage. Rahman et al. (2019) classified these
resource attributes into two categories: ex ante limits to competition (i.e., valuable and
rare attributes) and ex post limits to competition (i.e., inimitable and nonsubstitutable
attributes).
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The study director role is defined by the Code of Federal Regulations Title 21,
Volume 1, Part 58, Subpart B, section 58.33 (2020) which states the following:
For each nonclinical laboratory study, a scientist or other professional of
appropriate education, training, and experience, or combination thereof, shall be
identified as the study director. The study director has overall responsibility for
the technical conduct of the study, as well as for the interpretation, analysis,
documentation and reporting of results, and represents the single point of control.
Although the legal significance is well understood in the industry, the intangible value of
this human capital competency and the relationships developed by and with the study
director may not be completely appreciated in terms of a comparative business advantage
and competitive value.
The phrase study director was used 29 times in the context of an overarching
theme across seven of the nine study participants, which represents an average response
of 3.2 times per participant for this specific theme and 30.8% of total responses across the
three overarching themes (see Table 3). Eight of the 29 references (27.6%) were made by
three participants representing the CRO industry and the remaining 21 references (72.4%)
were made by the four participants representing the pharmaceutical/biotech industry. This
suggests that the pharmaceutical/biotech participants overwhelmingly considered the role
of the study director to be noteworthy in their responses. Descriptive words such as
experienced, good, individual, quality, and specific were used to qualify the role.
Additionally, the study director was discussed in terms of the relationship and trust factor
described in the previous section. Study Participant PharmBio1 indicated the following:

83
I mean, personally, what I'd like to see, where I see the value is, and the bonus for
me is if possible, I have the same study team or reasonably consistent study team
across all the studies. I have the same study director, the same pathologist
potentially working on the slides. So people have seen this and are familiar with
the program. They're familiar with me, with my company, et cetera. And I think
that increases the trust in the relationship. So I think there's the benefit there.
When asked what differentiates the preclinical CROs that they are doing business with
(i.e., strategic partnerships/relationships), participant PharmBio1 previously stated the
following:
I think the differences lie in the trust and the personal relationships that are built.
Honestly. I think most CROs are highly capable of doing the work. They all can
do it. Many have been around for a long time and some have, of course, acquired
others that have been around a long time. And so the subject matter experts, the
experienced study directors and study teams are there at all times. So they can all
do that. It's the communication, the support that you get.
When describing capacity constraints and strategy in terms of deciding what work is
outsourced to a CRO, Study Participant PharmBio2 explained the following:
Our strategy right now is all of our GLP work is outsourced 100% because we
don't have a GLP laboratory. So that's the first decision that we make point wise.
The next piece is the specific capability at a specific CRO. And on top of that, the
relationships or the experience we have with the specific study directors that are
going to be running our studies.
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Participant PharmBio2 continued:
The relationships with individual scientists [i.e., study directors], in my view, is
the most important and that kind of gets into trust. And my bedrock principle for
working with CROs is communication. So communication is the number one
reason why I'll stop using a provider.
When asked to describe the strategy used in deciding what work is outsourced to a CRO,
participant PharmBio4 stated the following:
I think we go to places that have certain expertise. And part of that is it's learned
over the years … that these partnerships develop … It’s experience with both the
client liaisons and importantly the study directors. And so I think there's a comfort
level that you get with people who over time learn, the specific way of writing
things and what ends up happening is as that partnership develops, it costs us less
time when we are reviewing reports, because we're talking the same language.
Applications to Professional Practice
In this study, I explored the experiences of key decision makers at
pharmaceutical/biotech companies and CROs to describe and understand the
collaborative approach to science and business that has fostered the strategic partnership
paradigm. The specific business problem researched for this study was that some leaders
of CRO and pharmaceutical/biotech companies lack strategies to develop strategic
partnerships in the drug discovery and development process. The results and findings of
this study are applicable to division leaders, client services personnel, procurement
groups, program managers, and study directors that directly or indirectly make business
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decisions that can impact a collaborative relationship between the service provider (CRO)
and the client (pharmaceutical/biotech companies).
Although some outsourced work by a pharmaceutical/biotech company to a CRO
may be in its simplest form transactional, the evolution of a partnership into the
intangible competency of a client relationship should be the business strategy for any
company aiming to achieve effective value creation and competitive advantage. The
comparative advantage theory expands on an organization’s tangible resources to include
intangible competencies such as organizational culture, brand equity, knowledge, human
capital (e.g., skills and knowledge of individual employees/teams), and relationships
(e.g., with study teams and study directors) that enable the achievement of superior
financial performance. This study highlighted an organization’s intangible resources and
inherent competencies as determinants of success. The human capital factor and focus on
relationships enable an organization to produce greater perceived benefits for similar
costs. These perceived benefits are defined by how well a partnership evolves into an
established relationship with a client. The relationship can be further strengthened by the
trust established between the study director (CRO) and the pharmaceutical/biotech
company. As suggested by participant CRO3, “A partnership is at the most simple level,
it's where I think there is a higher level of intimacy. There's a higher level of trust, a
higher level of just vulnerability.”
Implications for Social Change
The pharmaceutical drug discovery and development process is a daunting
process that can usually take 10 to 15 years and cost billions of dollars. To identify one
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effective and safe drug, millions of potential compounds and molecules are screened and
for every 5,000 to 10,000 potential drugs evaluated, ultimately only one will receive
approval from the FDA. To reduce the cost and time of drug development, most
pharmaceutical/biotech companies strategically outsource much of their discovery and
preclinical work/projects. By strategically outsourcing these activities, companies can
depend on the expertise of the outsourcing partner (i.e., CRO), thereby reducing costs
associated with having to introduce innovation.
The results of this study suggest that focused attention on the client relationship as
an evolution to the strategic partnership and a better understanding of how a client
perceives trust and associated risk, can improve efficiency and therefore also reduce
costs. These focused working relationships have the potential to help bring
pharmaceutical drugs to market faster, cheaper, and with improved efficacy because of a
clear understanding of expectations and the role each organization plays in the drug
approval process, the assumed risk each organization assumes in the relationship, and the
continued innovative approach to business and scientific collaboration. As stated by
participant CRO3:
Ultimately, that relationship is founded in the shared vision and mission of really
having a benefit on all of our mutual customer, which is the patient who
desperately, desperately deserves for a world class partnership. Because I think
that the better we can truly partner, we will deliver a higher quality product to the
patient and we will deliver it faster. And that will take time off of an already long
drug development cycle, which saves lives.
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By focusing on establishing lasting relationships, the CRO and pharmaceutical/biotech
industries have the potential to shorten drug development timelines, further improving
quality of life by providing a higher quality product to the patient, and ultimately saving
lives.
Recommendations for Action
The key senior level decision-makers who participated in this study provided
suggestions and insight on the strategies that CRO and pharmaceutical/biotech company
leaders use to develop strategic relationships during the drug discovery and development
process. Answers to the interview questions provided the basis for three overarching
themes and opinions presenting business strategies focused on engagement between the
CRO and pharmaceutical/biotech companies to create financially and scientifically
mutually beneficial collaborations. The recommendations associated with the 3
overarching themes of (a) defining a strategic/essential partnership, (b) understanding the
benefit of building a relationship, and (c) the study director is an essential asset, are listed
below in Table 6.
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Table 6
Recommendations for Action
Theme
Defining a strategic/essential

Recommendations
• Evolve to more focused relationships beyond the ‘transaction’

partnership

• Establish key contacts
• Maintain innovation
• Treat each other with respect but with accountability

Understanding the benefit of

• Establish trust

building a relationship

• Maintain constant/consistent communication
• Focus relationship on the SME/study director
• Create a higher level of business intimacy
• Understand inherent risk(s); perceived, individual, shared

The study director is an essential

•

Encourage substantive business relationships with the client

asset

•

Establish trust

•

Maintain constant/consistent communication

These recommendations for action will be made available to business
professionals within the pharmaceutical/biotech industries through online platforms,
industry publications, and/or market research literature. Additionally, these
recommendations will be made available to the study participants and/or specific
companies represented by the study participants.
Recommendations for Further Research
This qualitative multiple-case study included nine participants who were key
senior level decision-makers in the pharmaceutical, biotech, and CRO industries (e.g.,
company presidents/vice presidents, CEO, and directors). Although I maintain that the
multiple-case study research method was appropriate to draw conclusions from the lived
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experiences of the study participants and the number of participants was adequate to
represent the various industry sectors across a global representation of organizations
sufficient to reach data saturation, there are aspects of the study that could benefit from
further research and potentially more participants. The concept of trust in a business
relationship can be further investigated to establish the expectations for building that
trust. A longer duration evaluation of established business relationships can be conducted
to determine actual time saved and reduced costs associated with the drug approval
process. Additional research can be conducted to investigate the role of a pandemic on
the partnership/relationship paradigm. Specifically, how the COVID-19 pandemic
impacted CRO relationships with pharmaceutical/biotech companies racing to develop
vaccines and treatments during 2020 and 2021 can be explored, and how/if relationships
were made stronger/weaker by the expedited timing requirements can be investigated.
Reflections
The process of conducting this qualitative research study was informative and
provided insight to a question I had early in my career. While my career and experience
lend themselves to a very analytical and quantitative paradigm, the qualitative approach
to case study research was an intensive and often challenging learning process. The
substantial information that emerged from the semistructured interviews provided an
interesting and comprehensive data set for answering the research question.
Although I attempted to mitigate bias by contacting participants that I did not
know personally or had previously worked with, it was very difficult to secure study
participation. As a result, many of the study participants were colleagues that I knew and
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had worked with previously in my career. Realizing I may have bias with these specific
study participants, I adhered to preset guidelines and the interview protocol to ensure any
biases and assumptions, real or perceived, were limited as suggested by Yin (2014).
However, my previous relationships with some of the participants resulted in familiar
conversation during the interviews. Nonetheless, I was able to manage the interactions so
as not to influence the participants’ answers.
Conclusion
An organization’s intangible resources and inherent competencies are
determinants of success. The evolution of a partnership into the intangible competency of
a client relationship may likely define future business strategy for the industry.
Understanding and improving existing company processes and evaluating strategic
business relationships implemented between the pharmaceutical/biotech companies and
CROs can result in business opportunities that are mutually beneficial. By understanding
the importance of general business relationships, the intangible value of human capital
competency, the relationships developed with clients by that human capital, and the
significance that trust plays in how relationships are maintained and/or improved,
business leaders can implement strategies that provide comparative business advantage
and competitive value throughout the drug discovery and development process.
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Appendix A: Interview Protocol
Interview: Key nonclinical pharmaceutical industry decision makers’ insight describing
the attitudes and experiences they have toward strategic business collaborations with each
other, what risk responsibilities service providers (i.e., Contract Research Organizations)
assume in a scientific/business strategic partnership, and how those collaborations have
influenced the pharmaceutical research industry
Protocol:
A. The study and a general overview will be provided via a formal email and/or
telephone conversation.
B. The subsequent formal telephone or Skype interviews will begin with introductions
followed by an overview of the study.
C. Appreciation will be conveyed to each participant for agreeing to contribute in the
study, and each participant will be assured of the confidentiality of our conversations.
D. Each participant will be assigned an identifying code to protect his or her anonymity
and this identifying code will be defined at the beginning of each interview and
subsequent audio-recording.
E. The participants will be instructed as to the following:
1. Each participant will be asked to provide responses to 10 open-ended interview
questions (the interview should last approximately 30 to 45-minutes).
2. Each participant will be informed that they will be digitally (audio) recorded during
the interview to ensure accuracy of data and their responses.
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3. Each participant will be asked to share their lived experiences and/or perceptions
regarding strategic business collaborations, what risk responsibilities service
providers assume in a scientific/business strategic partnership, and how those
collaborations have influenced the pharmaceutical research industry.
F. Member-checking will be explained to each participant and a follow-up memberchecking interview will be scheduled to review data findings to ensure accuracy of
the data and to ensure that it is a correct representation of the participants’
perceptions.
G. Following the study conclusion, each participant will be provided a synopsis of the
study findings.
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Appendix B: Interview Questions
Appendix B lists the open-ended interview questions used to understand what risk
responsibilities service providers (i.e., Contract Research Organizations) assume in a
scientific/business strategic partnership with a pharmaceutical/biotech company client.
The following are the interview questions:
1. What do you think the role of a CRO is in a strategic partnership during drug
discovery and development?
2. What is your strategy in terms of deciding what work (i.e., projects, programs,
etc.) is outsourced to a CRO?
3. How would you describe a strategic partnership with a CRO during the drug
development process?
4. Describe the most important factors that influence your selection of a strategic
partner (ranked from most important to least important).
5. What do you think currently differentiates the preclinical CRO(s) that you
have strategic partnership(s) with and were similar strategies used to develop
that/those relationship(s)?
6. As strategic partnerships evolve, what are your concerns considering your
current partnerships/relationships and the expectations you have now and in
the future?
7. How do you measure the financial success of your outsourcing (strategic
partnership, if applicable) project(s)?
8. How do you assess and manage outsourcing (strategic partnership) risks?

114
9. Describe the risk-sharing responsibilities/assumptions you currently have with
your outsourcing partner.
10. What else can you add regarding strategies service providers (i.e., Contract
Research Organizations) and pharmaceutical/biotech companies use to
develop strategic partnerships during the drug discovery and development
process?

